*9B8DUV<(TTC]6TE*4
M$6U8+4O1Z_XD"IR\S/,J^W,JM5MQE,\.P8K6_" M=4BX*116PQKUK8(.;#F%
M!8@:A;FHQJF.\6V"@LVG8269QZ+JTP@'QW5Q\HF0SAN\MCV"KCOI$OF--@)^
M%$-/^SL.-DE(TUSFG=G,8%MKUY[)<%E]9L?1.N#^*YT=G2MY(&22:+*W%=R82T0Z=4@K:YYUPNELJ;G!P&A118N-
M,'VW=]3]X8PUWE(G,\560%UC_MN(;@.)435VB!L41._B1)MPZ8L:VXJ"U3OQ
M;2,HJ$\D8>7@.&IJ*%]J?V'6,^4W^[>Q1)L81!L]=]N+]>"PU3OLKQ?KJH\*
M0I/MG@T(W:/34Y\%% >9;
MH\?[YT!><8J_+S=Z*_=[>-8',RMNC(YR#D]' WVKV36EOA#Z'7Q%PXD(UJA9 7D;<)JJ',F9>J4SDR*@#E%2[ -1K8*Z
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M6.=W6Z/;3+*P<6UH6>*ZR_SIY/#@'8H5,<4Z/@O=I6$W"[%7VV7T?^G
M78KE=GG=%G\8FR:$T5BQCPRQL.-9V\I%>U?W7V^O1>\,24Z>3U,SIK$+CJ@,
MC0B&52FW%AX\&3K TN%1])2;>4Y6LHC]'E YEA5U6J2[A'Z4M*#+&1TZ;:.U
M)4:#A]'^E?FZWV\QXPL;NR%FE6KP",.X
MR/P=FJ([M-5D%$FE:KH=_M063'!H$XXC/CK#+A"SPUSI<<>J5(94K>/9G$(K
ME'?JWQ>($C<*@&=E\]#WH0V4*#%Q::R+R.!,)3JF:19ZPM5#[6X,%@F2#2S$
M$E^.2>4IKZ"=F"*0Z\"IC
MGV!EC&I"Q-,J83\V]#W":VYEM"M. 7WLE$4(O21B;'5!(!!(.-;+P3<-?OU4(H0T*
MFE(0 XVAZT&E6DU:G,$W=;Z/?%O M '3EF?1J\'#S8B>UN-G/;(3>46*C$ID
MDFMM].7W]JB-WCG&B*,9DO64>T2^Z#@1-QR61XM'F<197X88B$&2X02HK/T]
M0#T?7PX::^@,5*PTDU"^)L2);. CJ/THU'Z#A1,<*@^FW$69YR U4BIEHDS8A71P#&G32E*/
M4-0 +3&;;Y7V8_"2'0R&TD_C=/1DYMP(NB9RS64?(=UB-+2!R?5^@K-B;*PU
MZ"14X12D])5MQ[\ISH-/T/#%(1QDA0ACK%3B>-F"131RM&-3H8F;P)(<*J*(
M21QA]RJ^D&8=XK:\I\91\O=7J%_SGB^\<&"^:]/BT 23RM\=<.#G$A.8>BE4
M[OQM&]57S3+]#I:V:)/(W>!S4[?!80G+K)]4T3K#S4=S=WX0[L[;"P)XL(D
MAG1/PO E4\9?!LD5[^NT0;4T5*%QG):_"K[UX(6T"#G[)J-OVDM7BTQ-_7W0
MV0;+P"<,-5:"R"U7JB3[H!EJ*II_VV)OA%YX1PRBQX;RQZ,/[4T_LG26?O."
MC5/^98\H&4[1__S5/&U^/!SXW\P6R_TOCQA9IB">:'03;.VV3XYV/)6JOY2F
MX%_0QJ8L3<8?9TH"5VD!WD\,# U?2$'SD^K%?P%02P,$% @ -X O4W0F
MGL7, @ W@4 !@ !X;"]W;W)K]7[!B&IS1VG*3ME"0SN4'+]))) @S#\*#8FU@@2T:2D_;O6+&U
MEW/V(NWV=DK_,!FBA8=<2-,/,FN+RS T288Y,TU5H"3+6NF<61+U)C2%1I9Z
M4"[".(K.PIQQ&0QZ7C?3@YXJK> 29QI,F>=,/XY0J%T_: 4'Q9QO,NL4X:!7
ML TNT'XL9IJDL&9)>8[2<"5!X[H?#%N7HX[S]PZ?..[,T1E<)2NE?CCA.NT'
MD4L(!2;6,3#Z;7&,0C@B2N/GGC.H0SK@\?G _L[73K6LF,&Q$I]Y:K-^QN8,OU:,I.2[=I2RL)BLGG!W,43"+*?3J_N;R72^>*JU+S/>W2^GT(%3
M^!?U)4Q*S>4&;(9@^,-I[JX$"M131KB,&U ZY9(&'0P3
M]&M JQ%UNXUNMWMDG4%X^D)@Y62I0$N?6B6JU):4&MX'7=7[*AN:WMHB:),7U+;,[ZE<:>)TSAI)M/I T2N1$Q(@@% R^[7
M=Q>\6*(EIWU(1(+8W;-G+UCX9*'T5Y,B6GC(L\*<#E)KRU>CD8E3S(49JA(+
M^C)3.A>67O5\9$J-(G%">38*@^!@E M9#,Y.W-I[?7:B*IO) M]K,%6>"_UX
M@9E:G [&@W;A@YRGEA=&9R>EF.,=VD_E>TUOHTY+(G,LC%0%:)R=#L['KR[V
M>;_;\*?$A5EZ!O9DJM17?KE)3@I,'BILL\RL>GIX&@ "KS+C_85'OG1P.
M(*Z,57DC3 AR6=2_XJ'A84G@*-@@$#8"H<-=&W(HKX059R=:+4#S;M+\Y5
M)TW@9,%!N;.:ODJ2LV=WJ="8JBQ!;7Z&ZV^5M(^P?84S&4N[JL*F!JZ+!)-5^1%AZP"&+<"+\$6%OU7%$":!#V$0CE_0-^D<
MGCA]DTT.6Q5_[3O\3EF$O\ZGQFI*D[]?,+/?F=EW9O8WF7ES_N'ZS>WO5]
M[LC,'Y]N/GXA7J]?WUS>?%S+Z\OZWMU^O(8(]F!9\4\_'(7CPU^>J7\%'U,$
MI1-94*&!X1@;D 586KY4>2F*1XA5,4,-5:D*C]:EAH85MTMS-H-55'@Q4MU
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MGK @H-2<+?BMHH0@K%L'PS""DJ X"AT..E%X(VJI$@8PXU1X1*&-3]@XRF=P;'W'J&Y7)1+B#83M%
MC11?QS*=":@IYQBT,,L<]_EBCG=Z.=X4I'E6>V6E346,>:1VD4IBN"VV1D%?
MH"F-A&'W/CKB&-,C8>A_2S%+AG!#QUU"^4_N^<^#ZGOK("\3!^N(B_X';^*%
M+-M$FK>)--A$VO=8_V\D1NLYI$RK\^ZX86VU>V;*D&)IN:\2T2+SRFJ:R9BP
M$1.<'/CDMI++K49WQ=D[FKP;LF1.N+NM9J\IC=T>&"K+CVV.W1'PUPK0_QJ%2,FIFTFK6^NYGBA\0SZGBTH\+ U
MCIQG4R0JJ8=C4L6N9"LZ^?5"2W[Q$FEB57&K8']BE>?2\$!7OZ.QDB8K1T*C
M&Q]HWC0?'([02FC\O@:OQ668(EN5L_"3A4S2$G10PVF)$YE1Q"U%RQTB
MH$I7*(W>CA?4WG(PJY)WM$V_K5ORKY_.Q-B(LG;1-E\*^4J<&P;KUINA,:MF
M^5L;#H?;6T)DVA:.-0<=\@YF"[ U7[O>G 0-^7F.B:1X$L=+)P)W(%+J)3PQ
M$*\<-U'$=>(_A\H@R1KN(K
M79\O7I?A?4B]ULDJ>$!J,J9P5Q?'3(W!ZW>@#16SVCMD/65,@L@/#PZ?A7G9
M(/?0QIQKR0^N7(C>K;%/]R[7.Y8&E02G%K9Y0.NU2-*MM-US#F6JF.]1R'-Z
M$H4AHHQ1L71EN) V7=M:14SY;F3K^Z4@T.K.BMF,2^X=G15N N#\:'OU46BRRN,J>:[TX-FT?!=X*XVK/:HMY [FH--N2._2"*_"CJ-W>N&N]I;.LF
MN=46V+E]>7WKPY4>PA<1JWOX%>^%S^=;2[& J2HJXTX3:FYEYD;?M:HVH5]W
MV1@M7>ARU'-W;24VN73KNUVWVMV,S^L+X=/V^EI-1_]<4KO-<$:BP? P&M0#
M>/MB5>FNAU-EZ;+I'E.ZW:/F#?1]IFB^;U[80/?W@K-_ 5!+ P04 " W
M@"]3-*:I,00% :#@ &0 'AL+W=OE6XJF#?+2?1CV@9;.%A&*U$C*KO_]
MCJ0LNZGMM-@P&+!$ZEZ>NX?'(T]G2C^; M'"UU)(<]8IK*U.>CV3%5@RTU45
M2OHR5KIDEH9ZTC.51I9[I5+TDG[_L%*G$'SRWQ5GGN ,YCEDM[+V:_8Y-/ ?.7J:$\?\P"[+IH -9
M;:PJ&V5"4'(9GNQKDX<5A>/^!H6D44@\[N#(H[QBEIV?:C4#[:3)FGOQH7IM
M L>E(^7!:OK*2<^>OV=X2I!98L@%TD6PU^J&47TOX>)/TDWF(O;0--O;WT]4"ON,F$
MW,.7X<>G:[B]'CX\W5_?7G]Z7)?,
M[78^?7Z\AD-X+!#&2E#=<#D!RT8"P: U0,4%ECY>JK)B5 S"O,"*6L&4)=I\DJW-N,7\3?<0I"H@A/)/FF<*CLDQ$5ZCYE+F"
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M2/])B3-XC??H?^)]2ZEOY;UEEK(2O
M]]"(KZ!?7U.-I]_HE@(Y(::-.5L7R68#1][3-G@O8FO.).N.E;V5\WJ)>N)O
M)88\U]*&HWL[VUY\AN&\OQ0/MZ9;IB=$$ZV7,:FZ#:E#%>!O(F%@5>5/_R-E
MZ2[A7PNZO*%V O1]K)1=#)R#]CIX_@]02P,$% @ -X O4\)L3,IG @
M%04 !D !X;"]W;W)K&UL?51-;]LP#+WO5Q &
M"FS %CM.^K$B"=!D&=8![8IV[0[##HI-VT)MR9/H.OWWHV3'2X$V%UNB^!X?
M*5*S5IM'6R 2;*M2V7E0$-7G86B3 BMA1[I&Q2>9-I4@WIH\M+5!D7I0589Q
M%)V$E9 J6,R\[<8L9KJA4BJ\,6";JA+F>8FE;N?!.-@9;F5>D#.$BUDM&EPF&ZT?W>8RG0>1$X0E
M)N08!/^><(5EZ8A8QM^>,QA".N#^>L?^U>?.N6R$Q94N?\F4BGEP%D"*F6A*
MNM7M-^SS.79\B2ZM_T+;^4Y/ T@:2[KJP:R@DJK[BVU?ASW 6?0&(.X!L=?=
M!?(JOP@2BYG1+1CGS6QNX5/U:!8GE;N4.S)\*AE'BUM\0M7@+"0F'DM0&\DC)\MGT)DCE*2-5#G4@B0J HOF229HX;VH:Z.W[$W(WI_/1B='
M/@RO)D=,;&OTEQ *8;PFY#NO:-O]'$U^V7
M!;];:)P#GV=:TV[C @POX>(?4$L#!!0 ( #> +U,C1A0JK 0 *(* 9
M >&PO=V]R:W-H965T.CU Y$K$F 08 +3L_/H^@!2EU([3=GKA![#[=O=A
M=[&G6VWN;,;LZ*'(E3WK9LZ5L\' )AD7PO9UR0H[:VT*X?!K-@-;&A9I4"KR
M01Q%QX-"2-6=GX:U:S,_U97+I>)K0[8J"F$>SSG7V[/NL+M;6,I-YOS"8'Y:
MB@W?L/M<7AO\#5J45!:LK-2*#*_/NF^&L_,C+Q\$?I.\M0??Y"-9:7WG?SZD
M9]W(.\0Y)\XC"+SN^8+SW /!C2\-9K(G.;7C2MI:-3[J45-;IHE&&!X54]5L\-#P<*$RC
M[RC$C4(<_*X-!2_?"B?FIT9OR7AIH/F/$&K0AG-2^4.Y<0:[$GIN?L,;4.QH
MR:4V3JK-Z< !UF\.D@;BO(:(OP-Q3%=:N&)C1;<9T
MH8M2J$TS622$5LG5KE$HED22E4BQRN%"<=&%BC/';604ZDP:>T.FH<1
M]7J-;SMZ3:+UW1=42JA.MP_(&QY.7ML:7'E+=80>IF"7Z=3VZ=,39!*&&\"J
M!*2GHH5 VQ)*?@UDP$=3):XRW.MXNP4"8E"GFEAUU3JN50T+$;2H-,3L5<2]
MD+E8R5RZ1T)$EDL!>::U5&!8PN(!^_UOSBL3EMQ6/\/-K'-M= K7]F?H#5Y#
MRG_[O) )MYM]VHG/Z"W?H\&6?KGGO:W6(D08 -!N[SA8@JO(>V5?.?3%,M-*
M)ATOL94&"]92*L5&:>MD0ORED@$PG&0@BE.9A-!2=";S&, 3<%05X*^VTD.JAX =M:?6)@Q\=-P\>,
M+I!P4B14(""G3[2X#]R\USE2(@2]>'#L6U:SUJ>;<#/)K]ZY
MY\Z15H\[[GMUIG5^E+I[G(,2>;2."ZH7V0)2DG,MR%A;AC
M8WL@*,>=BO O&Z:L?'A5U+T86E*G5,>'ALIM0]TGV:QE\E:#]EGGLQ)5*AW"
M6B*=5 7VUD87Q ]--/6%!.,TCBCN32=C/$_B<6?7/7*-'!KVQO&4IM,1-H^&
M0P\+1Q.41TH;1JDUS4.DN-"D;\3^9H853!J6O?[T..YR8AP+DQ,/_HQ1[2J!9W34FTR._Q4AT?]#2'P"OT^F0\0<#:._$S(9^>TI
M:!GUQL>3_T!)!*WG*1F-CW] R(=K5=@![
M4\\=>_%Z>KL29B-1M#FOH1KU)^,NF7HBJG^<+L,4LM(.C(7/#$,D&R^ _;76
M;O?C#;1CZ?PO4$L#!!0 ( #> +U.Z9K1OC0( (,% 9 >&PO=V]R
M:W-H965T=Q;/,2);-]7:%R)TMM)",GFE5L*X.L"$Y2Q&F2',>2<15-1D%W:R8C79/@
M"F\-V%I*9EZF*/1F'!U&6\4=7Y7D%?%D5+$5SI$6U:UQ4MQ1"BY16:X5&%R.
MHXO#\^G0VP>#!XX;N[,'7TFF]:,7OA?C*/$)H<"(&YSQHO40@/A.;[YA6\^1Y^5:V+#"IK%-
MSR+(:TM:MLXN \E5\V7/[3WL.)PF'SBDK4,:\FX"A2R_,&*3D=$;,-[:T?PF
ME!J\77)<^9\R)^-.N?.CR;S.+#[5J AF:[?:44P.ZP_CO$5,&T3Z >(8KK2B
MTL),%5B\]8]=.EU.Z3:G:;H7^*-6?1@D/4B3]' /;]#5. B\P?_6"+\O,DO&
M=<2?/?AAAQ\&_/ C_&(ZG_UAE
M$"ZUK)AZ.6!59?2Z87)K:^R".84W?!NH5>[$8TY'3'CN69+TDB1Y)92,7"\+
M 1GF6B*LT?KT/0B?T>3;IB9L5=
M70*7SC7IGQQ%8)J1;P3251BS3),;VK MW2N)QANX\Z76M!5\@.[=G?P%4$L#
M!!0 ( #> +U/*MLC=\ , )$) 9 >&PO=V]R:W-H965TAWU(3$IWSSW/O9":;'SX&DM$@N?*NCC-2J+Z.L]C
M46*E8M_7Z/C-RH=*$6_#.H]U0*634V7ST6!PF5?*N&PV2<_NPVSB&[+&X7V
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M:U7@-&.D)8(KH='ML9&9G"!\W6R%U))=P)LDNQE(6#]#V2$ME0@_O;D:
MC08W=_/'M!K>G,'XO/5F7A_W!. !:Q\$H-]CZEO0'IPGCES81B,H:T&;6%@?
M&Q8.5"KB(6^L!L]APL9$(DFPB.%F&["]:QCA>"(/@/M2 [AE"LIM.:L3$Q-@S.1Z94^ 3^YA))^CY@@<*S-QZVQV [<%)6X .@)4KF_^FYH!G+5'Z1U-K+ R?Z3V95F:EM*\)4 6[_7X M.?F
M%J,E<@E8(Z43ZF2&6R8IP8IO.FE[9FIVE7:)RS$%/2_G5**"NG^LF?.#:[+"
ML$X? Q%2C=H;LWO:?6_,VVOVQ;S]6/FL A*'UO38#8XGB=.WRM\Y[@QSV1PD2R4NG>;\VP2
M1(X0"DRM0V"TK/$$A7! 1..AP0Q:E\[PN;Q%_^1CIU@6S.")$G<\L_DD^!A
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MC<'TLBH6Q),8&U<>ID-OC^W;PRGQ\PK#@3^).K>251FWF'5FEY%4;3]8##L):.D
M=YB,7EQTX:@WB(:]HSB!;N>.:/NNN O7*SQ!#
MR:RDK1NM/6W'U*SNSC_J]8R[8'K%I0&!2S*-^H<'09WV[<:JTO?J0EGJ?"_F
M-&I1.P6Z7RK*?+-Q#MKA/?T-4$L#!!0 ( #> +U-+=4(-/@, (L) 9
M >&PO=V]R:W-H965TW?)%;=Q!.QR5;X!W:
MS^6-IEW8>LEX@=)P)4'C?!*<#4[/1T[?*SQP7)F--;A,9DI]=YNK;!)$#A *
M3*WSP$@L\0*%<(X(QH_&9]"&=(:;Z[7W=SYWRF7%XH\85G-I\$;P+(<,XJ
M86_5Z@,V^1PY?ZD2QO^'5:,;!9!6QJJB,28$!9>U9(]-'?8QB!N#V..N WF4
ME\RRZ5BK%6BG3=[.XQW.!S!M9(V-_!69IC]:A\2N!9AO$9X'G8E!G7P8'?0^X1(%#*"6<2,3N%>6B=XE:KYD;M3:S)_@-:R8ULP%ZB?#! X:
MT;M0ODF3@U)I%;V_*_IB
M<9EQF?U!V;K25\94A-*G_PR82QK4JJ:_/XR.'24YDPL_/AO#-(R3/0'\UNMU
MAW;0-VKI&_TW^M*M7;8O;=VX-CIX1S?O),:W=H]O$+,=:#/?[^E9 !F1816D
MVTC:[>#81^J"]QMMS4_%-M["C0NR0+WPSP!#D2MIZ[NR/6U?&F?U!?NL7C]3
MKIE>4 <277,RC0Z/:4)T??77&ZM*?]W.E*7+VR]S>BVA=@KT?:Z476]<@/;]
M-?T)4$L#!!0 ( #> +U-[C:WAO@( #L& 9 >&PO=V]R:W-H965T
M$E\]GW?W7?Q7>9[I1_,#M'"H132++R=M=7,
M]TVVPY*9"U6AI).MTB6S9.K"-Y5&EC>@4OA1$(S]DG'I+>?-WDHOYZJV@DM<
M:3!U63+]XPJ%VB^\T#MNK'FQLV[#7\XK5N MVOMJIY:
M93B[&CG_QN$SQ[TY68-3LE'JP1D?\H47N(108&8= Z/7(UZC$(Z(TOC><7I]
M2 <\71_9WS7:29#5QJJR U,&)9?MFQVZ.IP TN %0-0!HB;O-E"3Y1MFV7*NU1ZT\R8VMVBD
M-FA*CDOW46ZMIE-..+N\Q8)*;&&-E=*6RP)>W;&-0/-Z[EOB=UY^UG%=M5S1
M"UQCN%'2[@R\E3GFO^)]RJM/+CHF=Q6=)?Q8RPN(@R%$012>X8M[L7'#%_^U
MV*^7&V,U78UO9^A'/?VHH1^]1$\=D]<"06VATBJO,VN R1PJ9KF+:U _\@S-
MR^EBAA5VGC9DGI?7V=IDZ66 DWI!H-
MGVS(5L*S:;>IJRV*(@95.LVS[#*MA#+)?!KW5G8^I<9K97!EP355)>SS$C6U
MLV24'#8>U+;T82.=3VNQQ4?TW^J592OM40I5H7&*#%C%
MK3M:0\AD3?04C+MBEF1!$&J4/B (_OS!&]0Z +&,WWO,I*<,@T=B0K*%,MRPX$IA$80IXG8KK!7&!\ZZL;+DUGC%_8Q!CK7R
M&(&M)7YAM:6@V@4:4;.U4]QDJ)_A?#2)VM;(WLA5*QH9!37\H&QK530*Y>(U
MNJA(4E4I%T9%9Q.3VC[G#Q8U8Q=GN.-IYOB^E8FR1!4@@H3S?#":9,/7;C\]
M:J\*[38.$0>1O>NT?K>?4XNN/5_ +U.8H+6F+04
M )(9 9 >&PO=V]R:W-H965T:3':,/R<^(0+\#(,HN>SY0L0?#2-Q?1+BI,]B$LEOUHR'6,A;
MOC&2F!/LY: P,*!IVD:(:=2;3O)G"SZ=L%0$-"(+#I(T##'_=4T"MKOL6;V7
M!U_HQA?9 V,ZB?&&+(EXBA=E?7Q#HTS0#[B3TIV
M2>T:9%-9,?:TP,>6>,T$%_8[HZ4$QIF]EP6)/E?L"O'FCW@IHE@
M80F6#$(:%?_QSW(A:@!KT * )0!V!: 2@+H"!B5@T!4P+ '#K@"[!-A= :,2
M,.H*<$J DT>W"$<>RQD6>#KA; =X-EI:RR[RA,C1,H0TRG)W*;C\EDJ_^DA\^(*[U;.=QL@,\[D$=F
MJ_=;/?P1
M/W./1K)$O&R6..6N+Y47G,GI+_-GYTVI6EBUZU0&U@!69 K"AZ-&8]NVFRD/
M*\I#+>5K@KD,CB"26],RS?5PR^R;YF]-*7@$=PC;HV]7].T.\,Q8$F"=9_(KO
MFW;*?'S :OQJN6Z+(:/:$!G5<3-SRU1UU-1RSW@;@"WQ])N")<5V LI?'6
MX-35SE+J;>EUM*O0S$L[]<0<.D[+4BOUM8[(+TY\X,H94X]PG,V]T;?=O=1:
M2F(MO<;>ET4+2,?-4];CFTK7/A6EII9>3I?I*B$_4KGZ +\IZ91R6N-3)QU4
M6@CU6M@MZK!!"MNB#I4.0KT.'HWZ$?S1J,-:UZO7OHY!ADJX(#IYD)7,07TO
MV[V3OBXMU2-MM\DX5-(&]=+VSF;ZNC1K[WS2:W;06GBH=Z,!
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M9&^HJY]AIO\ 4$L#!!0 ( #> +U.7F,ET)@( )8$ 9 >&PO=V]R
M:W-H965T3AQ:VR''2=A3'L#1LZVA9
M2-:-4?J@V#>QJ#X\28X[V(^?)#LFE*0O\X.M*]US[CGRE=)&Z6=3(EIX$5R:
M:51:6UT38O(2!35#5:%T*QNE!;4NU%MB*HVT""#!21+'ET10)J,L#7,+G:6J
MMIQ)7&@PM1!4_YDA5\TT&D7[B27;EM9/D"RMZ!97:!^JA781Z5D*)E :IB1H
MW$RCCZ/KV<3GAX0?#!MS, ;O9*W4LP]NBVD4>T'(,;>>@;K/#F^0CO?LGX)WYV5-#=XH_I,5MIQ&'R(H<$-K;I>J^8*=GPO/ERMNPAN:
M+C>.(*^-5:(#.P6"R?9+7[I]. D5R< 20=(@NZV4% YIY9FJ58-:)_MV/P@
M6 UH)XY)_U-65KM5YG V6R*G%@M84&T9&J"R@%5)-9:*%Z@-G,W14L;-.;R'
MN1["+YJK'7S&'87'>Q1KU$\P ";A>ZEJX^ F)=8)\_0D[T3,6A')"1%?:SF$
MA
M\N1$Y6^Z8-)U.K1>X"\<,]5N4,MT&9C\0=IEH_C"/RG9'9$PZ25,WI2PH*R
MM9*U\RU4+:T3,3A6OZ6Y.*B?3.)7MT_UEDD#'#<.%0^O'%RWIZ -
MK*I"YZV5=7T^4D! 5! !D !X;"]W;W)K&ULO5A1;^(X
M$'[?7V&AGFXK]4@<")2*(K7 ZGJZ[E;+]O9A=0\F&8C5)&9M!]I_?V,G)&D;
M4DXKE0=P''\SG\>3;S*,=T(^J A D\.VDA@H04EL>.Y[L!)&$\[D[&=NY.3L^CK29<";C#5O# O3]YD[BE5-:"7D"J>(B)1)6EYTK>C'W+,"N^(?#
M3M7&Q&QE*<2#N;@)+SNN800Q!-J88/BSA2G$L;&$/'X61CNE3P.LC_?6/]G-
MXV:63,%4Q-]YJ*/+SGF'A+!B6:R_BMV?4&S(-_8"$2O[37;%6K=#@DQID11@
M9)#P-/]ECT4@C@%X! >@="^@7@/ZQ +\ V*T[^=YMX&9,L\E8
MBAV19C5:,P,;?8O&>/'4),I"2[S+$:G)(3XA!E8(KPE-RG7*LSG,3QMTADBJ6A&CL:N1D/
M3E#PN,YY> =X4'(K4ATI,D]#")_C'=Q3N3%OO[%KK]7@7UG:)=[HC'BN1QOX
M3-OAG\6V2WJN@=-A WQVA/<]9>[U=/^?
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MGD#4.^BZ5F%H>WHS2;8LSIH2959@ZSY'+^(R+]8,:VO'FMO+[G
MZ4)^W()Y^MOTCE9"2]]7:6DEM;1=:^^R984ZCTD([>]12\2N.\=HT[IHH7)AK*
M>+.<>)7,>>TRMP_NYGDNG*'?7H#3'W@S"RC8\8LNJS-L >[*O>7Q@'Y1\)D_\ 4$L#!!0 ( #> +U,3H=%=\P, $L- 9 >&PO
M=V]R:W-H965T:NG+CJE(BBRTHS]S \X9N
MSGCAS*=V[%[.IZ+2&2_P7H*J\IS)EP5F8C=S?.=UX"/?I-H,N/-IR3:X0OU7
M>2^IY[8L,<^Q4%P4(#&9.=?^Y-8/#,#.^)OC3NVUP4A9"_%H.G?QS/',BC##
M2!L*1C];O,$L,TRTCJ>&U&G?:8#[[5?V7ZUX$K-F"F]$]HG'.ITY(P=B3%B5
MZ8]B]QLV@@:&+Q*9LO]AU\SU'(@JI47>@&D%.2_J7_;<&'$.(&@ P0' #T\
M^@V@?RX@; #A(:!_ C!H %:Z6VNWQBV99O.I%#N09C:QF89UWZ+)+UZ80%EI
M24\YX?1\E3*)J,3UA6EIQC-U ;_ BH(TKC($D4 D
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MQ$9U8LZ-%V1279(AYM0@CQ,IV5>CG)CZVM%!U95Z/I*:4?;
M&GYA2]V#\:6I[8^,7_O>9$FQ]O8)A0L].88A%^F)K8_=+XNJ/S-H7S>\4)!A
M0@OT>E=TD\BZ($TJ1E*Q1*2[N'L0?%OHE%9])))\S[GG'"=7R5ZJ%YT#('DMN- S+TX>"!;7.T!_X\*>D6'@&?RGME=G[+DK$"A&92$ 6;F;<(+Y<36^\*
MGAGL]=&:6"=K*5_LYELV\P(K"#BD:!FH^=K!$CBW1$;&KX;3:UM:X/'ZP'[C
MO!LO:ZIA*?EWEF$^\Z8>R6!#*XX/U\= C::51%@W8
M*"B8J+_I:Y/#$6 \/0&(&D#T%\ T[@;$#2!V1FMESM:*(ITG2NZ)LM6&S2Y<
M-@YMW#!AW^(C*O.4&1S.;RA3Y)GR"L@=4%TI,*\(R:<5(&5:Y?2_-W
MAXSL)*?(.,.W+C'])*-@$ 1]:L:MFO$':M*F\"@;&ULU5==3]LP%/TK5L0#2!N)DWZB-M)HA<8$$J*#/: ]N,E-
M8^'$G>VT\.]G.R$M(XT*ZL-X:7R3>T[.O3ZUG=&:BT>9 BCTE+%69
MZ\HHA8S(4[Z$7#])N,B(TJ%8N'(I@,06E#'7][R>FQ&:.^'(WKL1X8@7BM$<
M;@221981\7P.C*_'#G9>;MS21:K,#3<<+>/)KB,QXYG% !D*HB\KF !CADGK^%.1
M.O4[#7![_,)^88O7QLY*"JDXED%U@HRFI=7\E0U8@N .SL ?@7P]P4$%2"PA9;*;%E3HD@X$GR-
MA,G6;&9@>V/1NAJ:FVF<*:&?4HU3X06A MT35@"Z!B(+ 7J.%#J>@B*4R1/T
M%*" >()8I3,*:.*@D0J)0H1 2@K@3'2<6+X5I:/YCH%4$)SDD>4,"05
M499>:M:[V10='YV@(Y/W,^6%)'DL1Z[211EI;E05<%X6X.\HX$>1GZ+ ^X)\
MS\<-\$D[? J1AF,+]U[#7=W*NI]^W4_?\@7_5S\?KK0.=*E#^;NEBJ"N(K!5
M='9V1= 5,7^P6N&S5KXF0A#]NJ99*@F[EM"L':OP:] )1NYJ>RZ:DKK#.NF5
MUDZMM=.J=<+S%0A%Y[JC,WRV:#6.CB,SP9O
M3=[@L\$[?#:L)0[W\!G>QV?8VVP0WB=V&M[:Z/"!O39I9S0GK#.Y)!&,'7V$
MDB!6X(2H3>QF%\'^0?Y@,3-%H';]XC2;/Y>9MNLY;CSFX=R&RM/.^0Z&X=6,W7PC41"YI+Q"#1S-YI7_="E ?P,E!\
M:<^P&ULU55=;]HP
M%/TK5U$?6FEM0L+'5@%2*:O6:4BHK-U#U0>3W!"KCLUL!]I_OVL'4K:E/.UE
M+^!KWX]SSG6NAUNEGTV!:.&E%-*,@L+:]648FK3 DID+M49))[G2);-DZE5H
MUAI9YH-*$<91U ]+QF4P'OJ]N1X/564%ESC78*JR9/IU@D)M1T$GV&_<\55A
MW48X'J[9"A=H[]=S35;89,EXB=)P)4%C/@JN.I>3@?/W#@\=.7);,X+42/WAF
MBU'P,8 ,Z>V7W#'I^?RI4H8_PO;G6\40%H9J\I=,"$HN:S_V&;T%?8,JV9M 9R+IE,.1-@++.^LJ&"TZ-!CS,LEZB?
MX,05^5ZHRC"9F6%H20Y'*DQWU"H+==PBV]OO\#0,SCM<44]]X2#I>X:BMXW6AGB_DYM%F?)[T/@W#30N\7@.O
M=Q3>K3$5:>#%?9.#2V-UY?5H U*G[!\"Z4:#=B#]!DC_*)#K@LD5NK[E[DIL
MW)5HJ]W_JW8W3MI+#YK2@W_0(OH L/D VI -6MK3_1-:>##-2M0K/[,-I*J2
MMAYLS6[S+%S5T_#-O7Y39DROJ%%TY7,*C2X&5%K7<[HVK%K[V;A4EB:M7Q;T
MM*%V#G2>*V7WABO0/);C7U!+ P04 " W@"]323S_>< " "Y!@ &0
M 'AL+W=OP&??=]WWYW/E]%&Z1=3
M(EIXK80TXZ"T=G49AB8KL6+F7*U0TDFA=,4LF7H9FI5&EGM0)<(XB@9AQ;@,
M)B._=Z:3!U53']8XI";<9!+]AMW/-E:=U&.!FMV!(7:!]6=YJL
ML&7)>872<"5!8S$.KGJ7TZ'S]PZ/'#=F;PTNDU2I%V?G1VB3]DH23YLCZKJ*O*#?V%IW=O?CTYZ[WOC\)UAZB+5M3%45''*C5L!0[_^_JH(;%MR"Y!PXZK2Y+>'XK"O7%2H5[ZH6DH[5K:9K*TN^U<
MOFK&T2_W9JC/F5YR:6@L% 2-SH<46S>#LC&L6OGAE"I+H\XO2_JVH'8.=%XH
M97>&"]!^K28_ 5!+ P04 " W@"]31%P9T1H" 6!0 &0 'AL+W=O
M_OWM!EXX4%/[81#,_(8+Z:6)\ZUTFJ@.
M:R%AI9GIFH;KWTNHU7[N3;V#8RVV%5J'GR8MW\(CX-=VI8GJ7Q?:\._!-P-XKP_L'YUVTK+A!C)5?Q<%5G/OUF,%E+RK<:WVGV#0\\[RY:HV[LOV
M_=GXQF-Y9U U Y@R:(3L__QYJ,,1@'C. \(!$)X"X@N : !$3FB?F9-USY&G
MB59[INUI8K,+5QN')C5"VBX^HJ9=03A,U[ #V0%[?0_(16W>)#X2K=WT\X%B
MV5.$%RAF[$%)K S[( LH_L7[E,Z84WC(:1E>)?S2R0F+@KX7H)_=,5(\-9-GF&YZB3VG1V]
MXW OW)T^\2]IZ/L9_4O3OQ@/7&^%-*R&DBB#R0V-C.ZGL#=0M>XB;Q12U=VR
MHH<+M#U ^Z52>#!L@/$I3/\ 4$L#!!0 ( #> +U/1G1:-B0, \, 9
M >&PO=V]R:W-H965T49-F1:378UTLL4O?QN^/Q
M=)GNI?JN-P"&/)>%T#-O8\SV@^_K; ,ETU=R"P+?K*0JF<&E6OMZJX#EM5)9
M^&$0Q'[)N/#FTWKO0'*[ZSDO 2AN11$P6KF?:0?;FAL%6J)WSCL]+I\\'ZISIX#&;)--S(XBO/S6;F
MI1[)8<6JPCS*_2_0!C2V]C)9Z/HOV;>R@4>R2AM9MLI(4'+1_++G-A$G"FC'
MK1"V"F%?871!(6H5HCK0AJP.ZY89-I\JN2?*2J,U^U#GIM;&:+BPQ[@P"M]R
MU#/S!:SQ4 QYA*U4AHLU>7L+AO%"OR,_D05635X50.2*;)7,J\QHPD1.MLQP
MJZ9![7@&&F6?%K?D[9MWY WA@ORZD95&03WU#5):7W[6$ETW1.$%HIC<2V$V
MFOPL CQ.APT^+D25R0*WI,P"*F#Y^;UZL$ 3M1E/*KM1:_.
M^)UHKJ,MZV]?4)S<&2CU[P/.1IVS4>UL=,'9(^Q 5'@^*R5+ L\&E&!%6UB@
MG,?36!S7%FT7V,W#23B>^KO3G#F$ AIT0B]@QQWL>!#VD)E":B=8HQV?^AQ1
MV@,[%XK&<>(&BSNP>!#L"7-6R(P9R,D:!"A,H;T%+,<;R;51S/8B3"\V5PU.
M]O@,BZ9QV&-W" 67V)../1ED_\0%$]D1[CT18%R$R9GS<1#U ,]E,+ENOK3C
M2P?YON!ADR7@#0!BV#.6*MX"+C(L3Q=E>D8P2I*XA^D0FDPN%.>DXYP,3__U;M":?%D7O7P[9,*).]TT/,*&_Z@;
MM.HO;LLX3/MH#JDDN@1W[.$T&JZ&]ONW.'S_7E,6QZ9-1_]#61S;+AWNNW^K
M+!S-.$WZ7PF'%)VD]$+VC^V8#O?C'Y9&?/9U2M-^+W,(T?2D?AHV_V2TPERL
MZXE3DTQ6PC0C2+?;3;4?ZUFNMW]MI]UZ9#N::4;E>Z;67&A2P I-!E<)(JEF
M^FP61F[K 6XI#1Y(_;C!B1V4%<#W*RG-86$==/\#S/\"4$L#!!0 ( #>
M+U/VN&P.+ ( 4% 9 >&PO=V]R:W-H965TJ#22[$JAVGMD.HM!^_:R=D
M= (>E@?''_><>\[U1](H_6(* $MV4I1F&A365E>4FJP R^
M*:R;H&E2L0TLP?ZL%AI'M&?)N832<%42#>MI\&UX-1N[>!_PR*$Q!WWBG*R4
M>G>3X-0B<(!&36,3#\;>$:A'!$*..UXPSZE YXV-^S?_?>TS J$#RLOVS75>' T <
MG@!$'2#RNMM$7N4-LRQ-M&J(=M'(YCK>JD>C.%ZZ35E:C:L<<39=UBL#KS64
MEMQNL37DXPU8QH7Y1+X0- X9,Y8\W8-<@7Y.J,6D#DJS+L&L31"=2@#5@(3C
MSR0*H^$'0HDIF ;3MN_I*&KO#42]@QX>DS=@^ESMQ[V0\5FFVQWHC!L@E>89.$%M+; F?W?ZF,"6=G)0
MEW@03?ZI"CTXU>Z!N&=ZP['N M8("P<39-'MI6L'5E7^H*^4Q6OCNP6^4Z!=
M *ZOE;+[@;L[_ P %!( T !X
M;"]S='EL97,N>&ULW5AM:]LP$/XK1AVCA5''<>O&:QS8 H7!-@K-AWTK2BPG
M EGR9*5+^NNGLQSGI;K2]<.6SB&U=(_NN4=WY\ID6)NU8'<+QDRP*H6L,[(P
MIOH8AO5LP4I:GZN*28L42I?4V*F>AW6E&_AO!;#J).743_+C9)?[9-WZX%MZ^WDDNE
MF]@N@OL[;9 )L9".1"= +[Q!E&PXH:P[2\L9-F<6-\ @7M>+*NK,*YINNH
M?TFV#LW-!IDJG3/=A8G(QC0:"E: ',WG"[@;584 &J-*.\@YG2M)&PT;CW9@
M:6=,B#MX+GX4>]RK8J=R/:B;[(964#MT-&X"_+MLCGN7]G6\0<4?E/F\M-N1
MS1R:C=UJ5O!5,U\5G0",/<+9:56)]2?!Y[)D;O,O#C@:THU?L%":/]IHT"HS
M:V":! ],&S[;M?S2M)JPE=FTTZK -???H.:_F^W@>N\CD+8A\ ^6.TZ/4&+9'X\[YNW?Z=M8 WG(R
M\AW>FL0V:#!=LH$MA)AV8D>WX&\OY
MLDR[5;>0B';5=OP5MA!GO+[Q#%4%=.&/<$XDJ88 KWH[]$D
M0;*3P,=?'^PIB>,T]2. ^17$,8; TX@CF +0@"%QW)R#!^=1N#FGPNWO0*/?
M4$L#!!0 ( #> +U.7BKL-8?20$3;8T.P6BP^0"X99K>]
M9!:GT'0]>MDD@.L.C:U
MG7;MK]\E&:W3T=.^>'P"7XQYIM!LE*^_7QVGJ\A64
MPKTS:]!X9&%L*3P.[3)U:PNB<"L 7ZJ4]WK#M!12)ZIG_%9[5D)=B[IJ(%_.I0)!1,NSA@@MIG6]F-.L+9+P%G-R.
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M/PIIV950%;"O(%QEH?Y!2$X.NU0XF)9 L
MLD&V%RO;PRVL M?I*91"LM@.>5XF6PDI?V21!?+"/J&^Y%Y(%6)2!LEB*X22
M<6?WRBF'\,@.(777PR,IYJ1>U%10*
MB%,"XI$%1&)V+SHE(!Y90#1FYZ)3 N([$E"+&3X$GF75F![4M#\0V7=QC/
MA'I;U!+ P04 " W@"]3
M9(35>EB 9JKT?/K1V16VZW*WL8/KI3FG'+O?3K, O1GU9@%Z\\O'M@"]&?5F
M 7HSZLT"]&;4FP7HS:@W"]";46\6H#>CWBQ ;T:]68#>">J=O%-OY^^M<4O/
M8XWGOY-J/SUKEN/GY6,3WQ?)C+.&/U#'7U!+ P04 " W@"]3.6DC=8(!
M !,$P $P %M#;VYT96YT7U1Y<&5S72YX;6S-F,M.PS 017\ERA8UKETH
M#[7= %OH@A\PR:2QZI<\;FG_'B=]2* 2416)V<1*/'/OM4MAXPVQAM
M<9HW,?H'QK!LP$@LG >;=FH7C(SI-2R8E^52+H")X7#,2F]P5ME[37'JO52ECVF=K6WUS&>P=BM39U6"C/%ZE
M@IR==&AW?C;8][VN(01503:7(;Y(DZK81C.,6PU8]$N82(Y;(CGNB.2X)Y*##ZD$H4)43@6IG I3.16H6?_U_IUT+
M(Y4]^+/N)]KL$U!+ 0(4 Q0 ( #> +U,'04UB@0 +$ 0
M " 0 !D;V-0&UL4$L! A0#% @ -X O4RE8
MD&UL
M4$L! A0#% @ -X O4YE&PO=V]R:W-H965T&UL
M4$L! A0#% @ -X O4P%CA$35!@ >AP !@ ("!(@L
M 'AL+W=O +U/9[>>@
M308 ) : 8 " @2T2 !X;"]W;W)K*@ &
M@(&P& >&PO=V]R:W-H965T&UL4$L! A0#% @ -X O
M4W.*)]]&" )"< !@ ("!_1\ 'AL+W=O +U/^:.RAU 4 $H, 8
M " @7DH !X;"]W;W)K&PO=V]R:W-H
M965T&UL4$L! A0#% @ -X O4S@JJ8\8"P 7AT !@
M ("!KS( 'AL+W=O +U-T)I[%S ( -X% 8 " @?T] !X;"]W
M;W)K&PO=V]R:W-H965T +U,TIJDQ! 4 !H. 9 " @=I'
M !X;"]W;W)K&UL4$L! A0#% @ -X O4\)L
M3,IG @ %04 !D ("!%4T 'AL+W=O&PO=V]R:W-H965T +U.Z9K1OC0( (,% 9 " @994 !X;"]W;W)K&UL4$L! A0#% @ -X O4\JVR-WP P D0D !D
M ("!6E< 'AL+W=O&PO
M=V]R:W-H965T +U-+=4(-/@,
M (L) 9 " @7=> !X;"]W;W)K&UL4$L! A0#% @ -X O4WN-K>&^ @ .P8 !D ("!
M[&$ 'AL+W=O&PO=V]R:W-H965T +U.8H+6F+04 )(9 9
M " @&UL4$L! A0#%
M @ -X O4Y>8R70F @ E@0 !D ("!,FT 'AL+W=O&PO=V]R:W-H965T +U,3H=%=\P, $L- 9 " @6IT !X
M;"]W;W)K&UL4$L! A0#% @ -X O4RE-S-.=
M @ 2 < !D ("!E'@ 'AL+W=OP >&PO=V]R:W-H965T
M+U,6:FY$N0( #@' 9 " @:U^ !X;"]W;W)K&UL4$L! A0#% @ -X O4TD\_WG @ N08 !D
M ("!G8$ 'AL+W=O&PO=V]R
M:W-H965T +U/1G1:-B0, \,
M 9 " @>6& !X;"]W;W)K&UL
M4$L! A0#% @ -X O4_:X; XL @ !04 !D ("!I8H
M 'AL+W=O&PO +U.7BKL +U.@=QA_% , +H4 /
M " 3J1 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " W@"]39(35>E&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4 " W@"]3.6DC=8(! !,$P $P
M@ $*E@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 )@ F $$* "]EP
" !
end
XML
43
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
44
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
XML
45
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.21.2
html
92
254
1
true
24
0
false
4
false
false
R1.htm
000 - Document - Document And Entity Information
Sheet
http://www.gmedinnovations.com/role/DocumentAndEntityInformation
Document And Entity Information
Cover
1
false
false
R2.htm
001 - Statement - Unaudited Interim Condensed Consolidated Statements of Financial Position
Sheet
http://www.gmedinnovations.com/role/ConsolidatedCashFlow
Unaudited Interim Condensed Consolidated Statements of Financial Position
Statements
2
false
false
R3.htm
002 - Statement - Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss
Sheet
http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement
Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss
Statements
3
false
false
R4.htm
003 - Statement - Unaudited Interim Condensed Consolidated Statements of Changes in Equity (Deficit)
Sheet
http://www.gmedinnovations.com/role/ShareholdersEquityType2or3
Unaudited Interim Condensed Consolidated Statements of Changes in Equity (Deficit)
Statements
4
false
false
R5.htm
004 - Statement - Unaudited Interim Condensed Consolidated Statements of Cash Flow
Sheet
http://www.gmedinnovations.com/role/ConsolidatedCashFlow0
Unaudited Interim Condensed Consolidated Statements of Cash Flow
Statements
5
false
false
R6.htm
005 - Disclosure - Description of Business
Sheet
http://www.gmedinnovations.com/role/DescriptionofBusiness
Description of Business
Notes
6
false
false
R7.htm
006 - Disclosure - Significant Accounting Policies
Sheet
http://www.gmedinnovations.com/role/SignificantAccountingPolicies
Significant Accounting Policies
Notes
7
false
false
R8.htm
007 - Disclosure - Significant Events and Transactions in the Period
Sheet
http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriod
Significant Events and Transactions in the Period
Notes
8
false
false
R9.htm
008 - Disclosure - Related Parties and Shareholders
Sheet
http://www.gmedinnovations.com/role/RelatedPartiesandShareholders
Related Parties and Shareholders
Notes
9
false
false
R10.htm
009 - Disclosure - Shareholders' Equity (Deficit)
Sheet
http://www.gmedinnovations.com/role/ShareholdersEquityDeficit
Shareholders' Equity (Deficit)
Notes
10
false
false
R11.htm
010 - Disclosure - Fair Value Measurement
Sheet
http://www.gmedinnovations.com/role/FairValueMeasurement
Fair Value Measurement
Notes
11
false
false
R12.htm
011 - Disclosure - Revenue
Sheet
http://www.gmedinnovations.com/role/Revenue
Revenue
Notes
12
false
false
R13.htm
012 - Disclosure - Segment Reporting
Sheet
http://www.gmedinnovations.com/role/SegmentReporting
Segment Reporting
Notes
13
false
false
R14.htm
013 - Disclosure - Subsequent Events
Sheet
http://www.gmedinnovations.com/role/SubsequentEvents
Subsequent Events
Notes
14
false
false
R15.htm
014 - Disclosure - Accounting Policies, by Policy (Policies)
Sheet
http://www.gmedinnovations.com/role/AccountingPoliciesByPolicy
Accounting Policies, by Policy (Policies)
Policies
http://www.gmedinnovations.com/role/SignificantAccountingPolicies
15
false
false
R16.htm
015 - Disclosure - Shareholders' Equity (Deficit) (Tables)
Sheet
http://www.gmedinnovations.com/role/ShareholdersEquityDeficitTables
Shareholders' Equity (Deficit) (Tables)
Tables
http://www.gmedinnovations.com/role/ShareholdersEquityDeficit
16
false
false
R17.htm
016 - Disclosure - Fair Value Measurement (Tables)
Sheet
http://www.gmedinnovations.com/role/FairValueMeasurementTables
Fair Value Measurement (Tables)
Tables
http://www.gmedinnovations.com/role/FairValueMeasurement
17
false
false
R18.htm
017 - Disclosure - Segment Reporting (Tables)
Sheet
http://www.gmedinnovations.com/role/SegmentReportingTables
Segment Reporting (Tables)
Tables
http://www.gmedinnovations.com/role/SegmentReporting
18
false
false
R19.htm
018 - Disclosure - Description of Business (Details)
Sheet
http://www.gmedinnovations.com/role/DescriptionofBusinessDetails
Description of Business (Details)
Details
http://www.gmedinnovations.com/role/DescriptionofBusiness
19
false
false
R20.htm
020 - Disclosure - Significant Events and Transactions in the Period (Details)
Sheet
http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails
Significant Events and Transactions in the Period (Details)
Details
http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriod
20
false
false
R21.htm
021 - Disclosure - Related Parties and Shareholders (Details)
Sheet
http://www.gmedinnovations.com/role/RelatedPartiesandShareholdersDetails
Related Parties and Shareholders (Details)
Details
http://www.gmedinnovations.com/role/RelatedPartiesandShareholders
21
false
false
R22.htm
022 - Disclosure - Shareholders' Equity (Deficit) (Details)
Sheet
http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails
Shareholders' Equity (Deficit) (Details)
Details
http://www.gmedinnovations.com/role/ShareholdersEquityDeficitTables
22
false
false
R23.htm
023 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings
Sheet
http://www.gmedinnovations.com/role/ScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable
Shareholders' Equity (Deficit) (Details) - Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings
Details
http://www.gmedinnovations.com/role/ShareholdersEquityDeficitTables
23
false
false
R24.htm
024 - Disclosure - Fair Value Measurement (Details)
Sheet
http://www.gmedinnovations.com/role/FairValueMeasurementDetails
Fair Value Measurement (Details)
Details
http://www.gmedinnovations.com/role/FairValueMeasurementTables
24
false
false
R25.htm
025 - Disclosure - Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements
Sheet
http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable
Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements
Details
http://www.gmedinnovations.com/role/FairValueMeasurementTables
25
false
false
R26.htm
026 - Disclosure - Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements
Sheet
http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable
Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements
Details
http://www.gmedinnovations.com/role/FairValueMeasurementTables
26
false
false
R27.htm
027 - Disclosure - Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the convertible debenture financial statements
Sheet
http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3intheconvertibledebenturefinancialstatementsTable
Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the convertible debenture financial statements
Details
http://www.gmedinnovations.com/role/FairValueMeasurementTables
27
false
false
R28.htm
028 - Disclosure - Revenue (Details)
Sheet
http://www.gmedinnovations.com/role/RevenueDetails
Revenue (Details)
Details
http://www.gmedinnovations.com/role/Revenue
28
false
false
R29.htm
029 - Disclosure - Segment Reporting (Details) - Schedule of products and patient services
Sheet
http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable
Segment Reporting (Details) - Schedule of products and patient services
Details
http://www.gmedinnovations.com/role/SegmentReportingTables
29
false
false
R30.htm
030 - Disclosure - Subsequent Events (Details)
Sheet
http://www.gmedinnovations.com/role/SubsequentEventsDetails
Subsequent Events (Details)
Details
http://www.gmedinnovations.com/role/SubsequentEvents
30
false
false
All Reports
Book
All Reports
ea147376-6k_gmedical.htm
ea147376ex99-1_gmedical.htm
ea147376ex99-2_gmedical.htm
ea147376ex99-3_gmedical.htm
gmvd-20210630.xsd
gmvd-20210630_cal.xml
gmvd-20210630_def.xml
gmvd-20210630_lab.xml
gmvd-20210630_pre.xml
http://fasb.org/us-gaap/2021-01-31
http://xbrl.sec.gov/dei/2021
http://fasb.org/srt/2021-01-31
true
true
JSON
47
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"instance": {
"ea147376-6k_gmedical.htm ea147376ex99-1_gmedical.htm": {
"axisCustom": 0,
"axisStandard": 9,
"contextCount": 92,
"dts": {
"calculationLink": {
"local": [
"gmvd-20210630_cal.xml"
]
},
"definitionLink": {
"local": [
"gmvd-20210630_def.xml"
]
},
"inline": {
"local": [
"ea147376-6k_gmedical.htm",
"ea147376ex99-1_gmedical.htm"
]
},
"labelLink": {
"local": [
"gmvd-20210630_lab.xml",
"srt-doc-2021-01-31.xml",
"us-gaap-doc-2021-01-31.xml"
]
},
"presentationLink": {
"local": [
"gmvd-20210630_pre.xml"
]
},
"referenceLink": {
"local": [
"us-gaap-ref-2021-01-31.xml",
"srt-ref-2021-01-31.xml"
]
},
"schema": {
"local": [
"gmvd-20210630.xsd",
"xbrl-linkbase-2003-12-31.xsd",
"xl-2003-12-31.xsd",
"xlink-2003-12-31.xsd",
"negated-2009-12-16.xsd",
"us-gaap-2021-01-31.xsd",
"xbrl-instance-2003-12-31.xsd",
"types.xsd",
"extensible-enumerations-2.0.xsd",
"xbrldt-2005.xsd",
"ref-2006-02-27.xsd",
"us-types-2021-01-31.xsd",
"srt-types-2021-01-31.xsd",
"srt-2021-01-31.xsd",
"country-2021.xsd",
"srt-roles-2021-01-31.xsd",
"us-roles-2021-01-31.xsd",
"dei-2021.xsd",
"sic-2021.xsd",
"reference-2009-12-16.xsd",
"us-parts-codification-2021-01-31.xsd",
"dei-2021_doc.xsd",
"dei-2021_ref.xsd"
]
}
},
"elementCount": 261,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2021-01-31": 80,
"http://www.gmedinnovations.com/20210630": 5,
"http://xbrl.sec.gov/dei/2021": 14,
"total": 99
},
"keyCustom": 33,
"keyStandard": 221,
"memberCustom": 9,
"memberStandard": 15,
"nsprefix": "gmvd",
"nsuri": "http://www.gmedinnovations.com/20210630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"p",
"div",
"body",
"html"
],
"baseRef": "ea147376-6k_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:EntityRegistrantName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "000 - Document - Document And Entity Information",
"role": "http://www.gmedinnovations.com/role/DocumentAndEntityInformation",
"shortName": "Document And Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"div",
"body",
"html"
],
"baseRef": "ea147376-6k_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:EntityRegistrantName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "009 - Disclosure - Shareholders' Equity (Deficit)",
"role": "http://www.gmedinnovations.com/role/ShareholdersEquityDeficit",
"shortName": "Shareholders' Equity (Deficit)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "010 - Disclosure - Fair Value Measurement",
"role": "http://www.gmedinnovations.com/role/FairValueMeasurement",
"shortName": "Fair Value Measurement",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "011 - Disclosure - Revenue",
"role": "http://www.gmedinnovations.com/role/Revenue",
"shortName": "Revenue",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "012 - Disclosure - Segment Reporting",
"role": "http://www.gmedinnovations.com/role/SegmentReporting",
"shortName": "Segment Reporting",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "013 - Disclosure - Subsequent Events",
"role": "http://www.gmedinnovations.com/role/SubsequentEvents",
"shortName": "Subsequent Events",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "014 - Disclosure - Accounting Policies, by Policy (Policies)",
"role": "http://www.gmedinnovations.com/role/AccountingPoliciesByPolicy",
"shortName": "Accounting Policies, by Policy (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "015 - Disclosure - Shareholders' Equity (Deficit) (Tables)",
"role": "http://www.gmedinnovations.com/role/ShareholdersEquityDeficitTables",
"shortName": "Shareholders' Equity (Deficit) (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "016 - Disclosure - Fair Value Measurement (Tables)",
"role": "http://www.gmedinnovations.com/role/FairValueMeasurementTables",
"shortName": "Fair Value Measurement (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "017 - Disclosure - Segment Reporting (Tables)",
"role": "http://www.gmedinnovations.com/role/SegmentReportingTables",
"shortName": "Segment Reporting (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c48",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gmvd:InitialPublicOfferingDescription",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "018 - Disclosure - Description of Business (Details)",
"role": "http://www.gmedinnovations.com/role/DescriptionofBusinessDetails",
"shortName": "Description of Business (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c48",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gmvd:InitialPublicOfferingDescription",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c1",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "001 - Statement - Unaudited Interim Condensed Consolidated Statements of Financial Position",
"role": "http://www.gmedinnovations.com/role/ConsolidatedCashFlow",
"shortName": "Unaudited Interim Condensed Consolidated Statements of Financial Position",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c1",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c49",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "020 - Disclosure - Significant Events and Transactions in the Period (Details)",
"role": "http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails",
"shortName": "Significant Events and Transactions in the Period (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c49",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c67",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockSharesIssued",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "021 - Disclosure - Related Parties and Shareholders (Details)",
"role": "http://www.gmedinnovations.com/role/RelatedPartiesandShareholdersDetails",
"shortName": "Related Parties and Shareholders (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c67",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockSharesIssued",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c69",
"decimals": "-1",
"first": true,
"lang": null,
"name": "us-gaap:SaleOfStockPricePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "usdPershares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "022 - Disclosure - Shareholders' Equity (Deficit) (Details)",
"role": "http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails",
"shortName": "Shareholders' Equity (Deficit) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c69",
"decimals": "-1",
"first": true,
"lang": null,
"name": "us-gaap:SaleOfStockPricePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "usdPershares",
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c73",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockSharesAuthorized",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "023 - Disclosure - Shareholders' Equity (Deficit) (Details) - Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings",
"role": "http://www.gmedinnovations.com/role/ScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable",
"shortName": "Shareholders' Equity (Deficit) (Details) - Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c73",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockSharesAuthorized",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c77",
"decimals": "4",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "pure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "024 - Disclosure - Fair Value Measurement (Details)",
"role": "http://www.gmedinnovations.com/role/FairValueMeasurementDetails",
"shortName": "Fair Value Measurement (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c77",
"decimals": "4",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "pure",
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c1",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "025 - Disclosure - Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements",
"role": "http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable",
"shortName": "Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c1",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c76",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DerivativeLiabilitiesNoncurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "026 - Disclosure - Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements",
"role": "http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable",
"shortName": "Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c76",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DerivativeLiabilitiesNoncurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfShortTermDebtTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c83",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ConvertibleDebt",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "027 - Disclosure - Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the convertible debenture financial statements",
"role": "http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3intheconvertibledebenturefinancialstatementsTable",
"shortName": "Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the convertible debenture financial statements",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfShortTermDebtTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c83",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ConvertibleDebt",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": "3",
"first": true,
"lang": null,
"name": "gmvd:PatientServices",
"reportCount": 1,
"unique": true,
"unitRef": "pure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "028 - Disclosure - Revenue (Details)",
"role": "http://www.gmedinnovations.com/role/RevenueDetails",
"shortName": "Revenue (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": "3",
"first": true,
"lang": null,
"name": "gmvd:PatientServices",
"reportCount": 1,
"unique": true,
"unitRef": "pure",
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": "-3",
"first": true,
"lang": null,
"name": "gmvd:RevenuesFromExternalCustomers",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "029 - Disclosure - Segment Reporting (Details) - Schedule of products and patient services",
"role": "http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable",
"shortName": "Segment Reporting (Details) - Schedule of products and patient services",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"table",
"us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": "-3",
"first": true,
"lang": null,
"name": "gmvd:RevenuesFromExternalCustomers",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": "-3",
"first": true,
"lang": null,
"name": "gmvd:Services",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "002 - Statement - Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss",
"role": "http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement",
"shortName": "Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": "-3",
"first": true,
"lang": null,
"name": "gmvd:Services",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c90",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "030 - Disclosure - Subsequent Events (Details)",
"role": "http://www.gmedinnovations.com/role/SubsequentEventsDetails",
"shortName": "Subsequent Events (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c90",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c25",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "003 - Statement - Unaudited Interim Condensed Consolidated Statements of Changes in Equity (Deficit)",
"role": "http://www.gmedinnovations.com/role/ShareholdersEquityType2or3",
"shortName": "Unaudited Interim Condensed Consolidated Statements of Changes in Equity (Deficit)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c25",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "004 - Statement - Unaudited Interim Condensed Consolidated Statements of Cash Flow",
"role": "http://www.gmedinnovations.com/role/ConsolidatedCashFlow0",
"shortName": "Unaudited Interim Condensed Consolidated Statements of Cash Flow",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": "-3",
"lang": null,
"name": "us-gaap:DepreciationDepletionAndAmortization",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "005 - Disclosure - Description of Business",
"role": "http://www.gmedinnovations.com/role/DescriptionofBusiness",
"shortName": "Description of Business",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "006 - Disclosure - Significant Accounting Policies",
"role": "http://www.gmedinnovations.com/role/SignificantAccountingPolicies",
"shortName": "Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gmvd:SignificantEventsAndTransactionsInThePeriodTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "007 - Disclosure - Significant Events and Transactions in the Period",
"role": "http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriod",
"shortName": "Significant Events and Transactions in the Period",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "gmvd:SignificantEventsAndTransactionsInThePeriodTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "008 - Disclosure - Related Parties and Shareholders",
"role": "http://www.gmedinnovations.com/role/RelatedPartiesandShareholders",
"shortName": "Related Parties and Shareholders",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "ea147376ex99-1_gmedical.htm",
"contextRef": "c0",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 24,
"tag": {
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentInformationLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
}
}
},
"localname": "DocumentInformationLineItems",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "stringItemType"
},
"dei_DocumentInformationTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
}
}
},
"localname": "DocumentInformationTable",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "stringItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r349"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r349"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.gmedinnovations.com/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"gmvd_AdjustmentstoCashProvidedbyUsedinOperatingActivities": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Total adjustments.",
"label": "AdjustmentstoCashProvidedbyUsedinOperatingActivities",
"totalLabel": "Total adjustments"
}
}
},
"localname": "AdjustmentstoCashProvidedbyUsedinOperatingActivities",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_CLAMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "CLAMember",
"terseLabel": "CLA [Member]"
}
}
},
"localname": "CLAMember",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"gmvd_CashConsideration": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of cash consideration.",
"label": "CashConsideration",
"terseLabel": "Cash consideration"
}
}
},
"localname": "CashConsideration",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "monetaryItemType"
},
"gmvd_ChangeInFairValueOfConvertibleDebenture": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 5.0,
"parentTag": "gmvd_AdjustmentstoCashProvidedbyUsedinOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Change in fair value of convertible debenture.",
"label": "ChangeInFairValueOfConvertibleDebenture",
"terseLabel": "Change in fair value of convertible debenture"
}
}
},
"localname": "ChangeInFairValueOfConvertibleDebenture",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_ChangeInRestrictedDeposit": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Change in restricted deposit.",
"label": "ChangeInRestrictedDeposit",
"terseLabel": "Change in restricted deposit"
}
}
},
"localname": "ChangeInRestrictedDeposit",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_ChangesDuringThePeriodAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "ChangesDuringThePeriodAbstract",
"terseLabel": "Changes during the period:"
}
}
},
"localname": "ChangesDuringThePeriodAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "stringItemType"
},
"gmvd_ChangesInAssetsAndLiabilitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "ChangesInAssetsAndLiabilitiesAbstract",
"terseLabel": "Changes in assets and liabilities:"
}
}
},
"localname": "ChangesInAssetsAndLiabilitiesAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "stringItemType"
},
"gmvd_ComprehensiveLossForThePeriodAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "ComprehensiveLossForThePeriodAbstract",
"terseLabel": "Comprehensive loss for the period:"
}
}
},
"localname": "ComprehensiveLossForThePeriodAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "stringItemType"
},
"gmvd_ConversionOfConvertibleDebentureIntoFinancialLiability": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Conversion of convertible debenture into financial liability.",
"label": "ConversionOfConvertibleDebentureIntoFinancialLiability",
"terseLabel": "Conversion of convertible debenture into financial liability"
}
}
},
"localname": "ConversionOfConvertibleDebentureIntoFinancialLiability",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_ConversionOfConvertibleDebentureIntoShares": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Conversion of convertible debenture into shares.",
"label": "ConversionOfConvertibleDebentureIntoShares",
"terseLabel": "Conversion of convertible debenture into shares"
}
}
},
"localname": "ConversionOfConvertibleDebentureIntoShares",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_ConversionOfLoanFromControllingShareholderIntoShares": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Conversion of loan from controlling shareholder into shares.",
"label": "ConversionOfLoanFromControllingShareholderIntoShares",
"terseLabel": "Conversion of loan from controlling shareholder into shares"
}
}
},
"localname": "ConversionOfLoanFromControllingShareholderIntoShares",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_CostOfServices": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 1.0,
"parentTag": "us-gaap_CostOfRevenue",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cost of services.",
"label": "CostOfServices",
"terseLabel": "Cost of services"
}
}
},
"localname": "CostOfServices",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"gmvd_DecreaseInInventories": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Decrease in inventories.",
"label": "DecreaseInInventories",
"terseLabel": "Decrease in inventories"
}
}
},
"localname": "DecreaseInInventories",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_DecreaseInOtherAccountsReceivable": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Decrease in other accounts receivable.",
"label": "DecreaseInOtherAccountsReceivable",
"terseLabel": "Decrease in other accounts receivable"
}
}
},
"localname": "DecreaseInOtherAccountsReceivable",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_DecreaseIncreaseInTradeReceivable": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Decrease (Increase) in trade receivable.",
"label": "DecreaseIncreaseInTradeReceivable",
"terseLabel": "Decrease (Increase) in trade receivable"
}
}
},
"localname": "DecreaseIncreaseInTradeReceivable",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_DocumentAndEntityInformationAbstract": {
"auth_ref": [],
"localname": "DocumentAndEntityInformationAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"xbrltype": "stringItemType"
},
"gmvd_DrYacovGevaMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "DrYacovGevaMember",
"terseLabel": "Dr. Yacov Geva [Member]"
}
}
},
"localname": "DrYacovGevaMember",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/RelatedPartiesandShareholdersDetails"
],
"xbrltype": "domainItemType"
},
"gmvd_ExerciseOptionToPurchaseWarrants": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Exercise option to purchase warrants.",
"label": "ExerciseOptionToPurchaseWarrants",
"terseLabel": "Exercise option to purchase warrants"
}
}
},
"localname": "ExerciseOptionToPurchaseWarrants",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "sharesItemType"
},
"gmvd_FairValueMeasurementDetailsScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements [Line Items]"
}
}
},
"localname": "FairValueMeasurementDetailsScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsLineItems",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable"
],
"xbrltype": "stringItemType"
},
"gmvd_FairValueMeasurementDetailsScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Measurement (Details) - Schedule of liabilities that are measured at fair value in the financial statements [Table]"
}
}
},
"localname": "FairValueMeasurementDetailsScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable"
],
"xbrltype": "stringItemType"
},
"gmvd_FairValueMeasurementDetailsScheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements [Line Items]"
}
}
},
"localname": "FairValueMeasurementDetailsScheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsLineItems",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable"
],
"xbrltype": "stringItemType"
},
"gmvd_FairValueMeasurementDetailsScheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Measurement (Details) - Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements [Table]"
}
}
},
"localname": "FairValueMeasurementDetailsScheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable"
],
"xbrltype": "stringItemType"
},
"gmvd_FinanceExpensesNet": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Finance expenses, net.",
"label": "FinanceExpensesNet",
"terseLabel": "Finance expenses, net"
}
}
},
"localname": "FinanceExpensesNet",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "monetaryItemType"
},
"gmvd_FinanceIncome": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 2.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Financial Income is the revenue generated by the temporary surplus cash invested in short-term investments and Marketable securities. It also includes foreign exchange gains on Debt and write-backs on provisions and Charges related to financial operations.",
"label": "FinanceIncome",
"terseLabel": "Finance income"
}
}
},
"localname": "FinanceIncome",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"gmvd_FiveOrdinarySharesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "FiveOrdinarySharesMember",
"terseLabel": "Five ordinary shares [Member]"
}
}
},
"localname": "FiveOrdinarySharesMember",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"gmvd_InitialAlphaCLAMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "InitialAlphaCLAMember",
"terseLabel": "Initial Alpha CLA [Member]"
}
}
},
"localname": "InitialAlphaCLAMember",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"gmvd_InitialPublicOfferingDescription": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Initial public offering description.",
"label": "InitialPublicOfferingDescription",
"terseLabel": "Initial public offering description"
}
}
},
"localname": "InitialPublicOfferingDescription",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/DescriptionofBusinessDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_InitialPublicsOfferingDescription": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Description of initial public offering.",
"label": "InitialPublicsOfferingDescription",
"terseLabel": "Initial public offering, description"
}
}
},
"localname": "InitialPublicsOfferingDescription",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_LiabilitiesAndShareholderSAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "LiabilitiesAndShareholderSAbstract",
"terseLabel": "Liabilities and Shareholder\u2019s"
}
}
},
"localname": "LiabilitiesAndShareholderSAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "stringItemType"
},
"gmvd_LoanFromControllingShareholder": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of loan from controlling shareholder.",
"label": "LoanFromControllingShareholder",
"terseLabel": "Loan from controlling shareholder"
}
}
},
"localname": "LoanFromControllingShareholder",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"gmvd_LongTermLoans": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of long term loans.",
"label": "LongTermLoans",
"terseLabel": "Long term loans"
}
}
},
"localname": "LongTermLoans",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"gmvd_LossForThePeriodAttributedToAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "LossForThePeriodAttributedToAbstract",
"terseLabel": "Loss for the period attributed to:"
}
}
},
"localname": "LossForThePeriodAttributedToAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "stringItemType"
},
"gmvd_OneOrdinarySharesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "OneOrdinarySharesMember",
"terseLabel": "One ordinary shares [Member]"
}
}
},
"localname": "OneOrdinarySharesMember",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"gmvd_OtherComprehensiveIncomeNetOfTaxAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "OtherComprehensiveIncomeNetOfTaxAbstract",
"terseLabel": "Other comprehensive income, net of tax:"
}
}
},
"localname": "OtherComprehensiveIncomeNetOfTaxAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "stringItemType"
},
"gmvd_OtherReserve": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of other reserve.",
"label": "OtherReserve",
"terseLabel": "Other reserve"
}
}
},
"localname": "OtherReserve",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"gmvd_PPPMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "PPPMember",
"terseLabel": "Paycheck Protection Program [Member]"
}
}
},
"localname": "PPPMember",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"gmvd_PatientServices": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "PatientServices",
"terseLabel": "Patient services"
}
}
},
"localname": "PatientServices",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/RevenueDetails"
],
"xbrltype": "percentItemType"
},
"gmvd_PatientServicesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "PatientServicesMember",
"terseLabel": "Patient Services [Member]"
}
}
},
"localname": "PatientServicesMember",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "domainItemType"
},
"gmvd_PublicOfferingPricePerUnitPercentage": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Public offering price per unit percentage.",
"label": "PublicOfferingPricePerUnitPercentage",
"terseLabel": "Public offering price per unit percentage"
}
}
},
"localname": "PublicOfferingPricePerUnitPercentage",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "percentItemType"
},
"gmvd_RelatedPartiesandShareholdersDetailsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Related Parties and Shareholders (Details) [Line Items]"
}
}
},
"localname": "RelatedPartiesandShareholdersDetailsLineItems",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/RelatedPartiesandShareholdersDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_RelatedPartiesandShareholdersDetailsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Related Parties and Shareholders (Details) [Table]"
}
}
},
"localname": "RelatedPartiesandShareholdersDetailsTable",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/RelatedPartiesandShareholdersDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_RepaymentOfFinancialLiability": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Repayment of financial liability.",
"label": "RepaymentOfFinancialLiability",
"negatedLabel": "Repayment of financial liability"
}
}
},
"localname": "RepaymentOfFinancialLiability",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"gmvd_RevenueAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "RevenueAbstract",
"terseLabel": "Revenue:"
}
}
},
"localname": "RevenueAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "stringItemType"
},
"gmvd_RevenueProducts": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 1.0,
"parentTag": "us-gaap_Revenues",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Revenue products.",
"label": "RevenueProducts",
"terseLabel": "Products"
}
}
},
"localname": "RevenueProducts",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"gmvd_RevenuesFromExternalCustomers": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Revenues from external customers.",
"label": "RevenuesFromExternalCustomers",
"terseLabel": "Revenues from external customers"
}
}
},
"localname": "RevenuesFromExternalCustomers",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "monetaryItemType"
},
"gmvd_ScheduleOfConferUponTheirHoldersTheRightToReceiveNoticeToParticipateAndVoteInGeneralMeetingsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings [Abstract]"
}
}
},
"localname": "ScheduleOfConferUponTheirHoldersTheRightToReceiveNoticeToParticipateAndVoteInGeneralMeetingsAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"xbrltype": "stringItemType"
},
"gmvd_ScheduleOfLiabilitiesThatAreMeasuredAtFairValueInTheFinancialStatementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Schedule of liabilities that are measured at fair value in the financial statements [Abstract]"
}
}
},
"localname": "ScheduleOfLiabilitiesThatAreMeasuredAtFairValueInTheFinancialStatementsAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"xbrltype": "stringItemType"
},
"gmvd_ScheduleOfLiabilitiesThatAreMeasuredAtLevel3InTheConvertibleDebentureFinancialStatementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Schedule of liabilities that are measured at level 3 in the convertible debenture financial statements [Abstract]"
}
}
},
"localname": "ScheduleOfLiabilitiesThatAreMeasuredAtLevel3InTheConvertibleDebentureFinancialStatementsAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"xbrltype": "stringItemType"
},
"gmvd_ScheduleOfLiabilitiesThatAreMeasuredAtLevel3InTheDerivativeLiabilityWarrantsFinancialStatementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements [Abstract]"
}
}
},
"localname": "ScheduleOfLiabilitiesThatAreMeasuredAtLevel3InTheDerivativeLiabilityWarrantsFinancialStatementsAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"xbrltype": "stringItemType"
},
"gmvd_ScheduleOfProductsAndPatientServicesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Schedule of products and patient services [Abstract]"
}
}
},
"localname": "ScheduleOfProductsAndPatientServicesAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"xbrltype": "stringItemType"
},
"gmvd_SegmentLoss": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Segment loss.",
"label": "SegmentLoss",
"terseLabel": "Segment loss"
}
}
},
"localname": "SegmentLoss",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "monetaryItemType"
},
"gmvd_Services": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 2.0,
"parentTag": "us-gaap_Revenues",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Revenue services.",
"label": "Services",
"negatedLabel": "Services"
}
}
},
"localname": "Services",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"gmvd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Description of reason for increase (decrease), classified as other, in number of awards under share-based compensation arrangement by share based payment award fair value assumptions expected volatility rate.",
"label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription",
"terseLabel": "Expected volatility ,description"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateDescription",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/FairValueMeasurementDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_ShareholderSEquityDeficitAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "ShareholderSEquityDeficitAbstract",
"terseLabel": "Shareholder\u2019s Equity (Deficit)"
}
}
},
"localname": "ShareholderSEquityDeficitAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "stringItemType"
},
"gmvd_ShareholdersEquityDeficitDetailsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Shareholders' Equity (Deficit) (Details) [Line Items]"
}
}
},
"localname": "ShareholdersEquityDeficitDetailsLineItems",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_ShareholdersEquityDeficitDetailsScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Shareholders' Equity (Deficit) (Details) - Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings [Line Items]"
}
}
},
"localname": "ShareholdersEquityDeficitDetailsScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsLineItems",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable"
],
"xbrltype": "stringItemType"
},
"gmvd_ShareholdersEquityDeficitDetailsScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Shareholders' Equity (Deficit) (Details) - Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings [Table]"
}
}
},
"localname": "ShareholdersEquityDeficitDetailsScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable"
],
"xbrltype": "stringItemType"
},
"gmvd_ShareholdersEquityDeficitDetailsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Shareholders' Equity (Deficit) (Details) [Table]"
}
}
},
"localname": "ShareholdersEquityDeficitDetailsTable",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_ShortTermLoanAndCurrentPortionOfLongtermLoans": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of short term loan and current portion of long-term loans.",
"label": "ShortTermLoanAndCurrentPortionOfLongtermLoans",
"terseLabel": "Short term loan and current portion of long-term loans"
}
}
},
"localname": "ShortTermLoanAndCurrentPortionOfLongtermLoans",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"gmvd_ShortTermPortionOfLeaseLiability": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 6.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of short term portion of lease liability.",
"label": "ShortTermPortionOfLeaseLiability",
"terseLabel": "Short term portion of lease liability"
}
}
},
"localname": "ShortTermPortionOfLeaseLiability",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"gmvd_SignificantEventsAndTransactionsInThePeriodAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Significant Events And Transactions In The Period [Abstract]"
}
}
},
"localname": "SignificantEventsAndTransactionsInThePeriodAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"xbrltype": "stringItemType"
},
"gmvd_SignificantEventsAndTransactionsInThePeriodTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of significant events and transactions in the period.",
"label": "SignificantEventsAndTransactionsInThePeriodTextBlock",
"terseLabel": "SIGNIFICANT EVENTS AND TRANSACTIONS IN THE PERIOD"
}
}
},
"localname": "SignificantEventsAndTransactionsInThePeriodTextBlock",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriod"
],
"xbrltype": "textBlockItemType"
},
"gmvd_SignificantEventsandTransactionsinthePeriodDetailsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Significant Events and Transactions in the Period (Details) [Line Items]"
}
}
},
"localname": "SignificantEventsandTransactionsinthePeriodDetailsLineItems",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_SignificantEventsandTransactionsinthePeriodDetailsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Significant Events and Transactions in the Period (Details) [Table]"
}
}
},
"localname": "SignificantEventsandTransactionsinthePeriodDetailsTable",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_SubsequentAlphaCLAMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "SubsequentAlphaCLAMember",
"terseLabel": "Subsequent alpha CLA [Member]"
}
}
},
"localname": "SubsequentAlphaCLAMember",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"gmvd_SubsequentEventsDetailsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Subsequent Events (Details) [Line Items]"
}
}
},
"localname": "SubsequentEventsDetailsLineItems",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SubsequentEventsDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_SubsequentEventsDetailsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Subsequent Events (Details) [Table]"
}
}
},
"localname": "SubsequentEventsDetailsTable",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SubsequentEventsDetails"
],
"xbrltype": "stringItemType"
},
"gmvd_TotalComprehensiveLossForThePeriodAttributedToAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "TotalComprehensiveLossForThePeriodAttributedToAbstract",
"terseLabel": "Total comprehensive loss for the period attributed to:"
}
}
},
"localname": "TotalComprehensiveLossForThePeriodAttributedToAbstract",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "stringItemType"
},
"gmvd_TotalComprehensivelossForThePeriod": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total comprehensive loss for the period.",
"label": "TotalComprehensivelossForThePeriod",
"totalLabel": "Total comprehensive loss"
}
}
},
"localname": "TotalComprehensivelossForThePeriod",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"gmvd_TotalShareholdersEquityMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "TotalShareholdersEquityMember",
"terseLabel": "Total"
}
}
},
"localname": "TotalShareholdersEquityMember",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "domainItemType"
},
"gmvd_TranslationReserve": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of translation reserve.",
"label": "TranslationReserve",
"terseLabel": "Translation reserve"
}
}
},
"localname": "TranslationReserve",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"gmvd_WarrantsAmount": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of warrants.",
"label": "WarrantsAmount",
"terseLabel": "Warrants amount"
}
}
},
"localname": "WarrantsAmount",
"nsuri": "http://www.gmedinnovations.com/20210630",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "monetaryItemType"
},
"srt_BankLoans": {
"auth_ref": [
"r351"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of short-term bank loan secured by broker-dealer customer's security.",
"label": "Broker-Dealer, Bank Loan, Short-term",
"terseLabel": "Loan received"
}
}
},
"localname": "BankLoans",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "monetaryItemType"
},
"srt_OwnershipAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
"label": "Ownership [Axis]"
}
}
},
"localname": "OwnershipAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/RelatedPartiesandShareholdersDetails"
],
"xbrltype": "stringItemType"
},
"srt_ProductOrServiceAxis": {
"auth_ref": [
"r145",
"r221",
"r223",
"r308",
"r337",
"r338"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by product and service, or group of similar products and similar services.",
"label": "Product and Service [Axis]"
}
}
},
"localname": "ProductOrServiceAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "stringItemType"
},
"srt_ProductsAndServicesDomain": {
"auth_ref": [
"r145",
"r221",
"r223",
"r308",
"r337",
"r338"
],
"lang": {
"en-us": {
"role": {
"documentation": "Product or service, or a group of similar products or similar services.",
"label": "Product and Service [Domain]"
}
}
},
"localname": "ProductsAndServicesDomain",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "domainItemType"
},
"srt_ScenarioForecastMember": {
"auth_ref": [
"r111",
"r234",
"r350"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
"label": "Forecast [Member]",
"terseLabel": "Forecast [Member]"
}
}
},
"localname": "ScenarioForecastMember",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SubsequentEventsDetails"
],
"xbrltype": "domainItemType"
},
"srt_StatementScenarioAxis": {
"auth_ref": [
"r111",
"r115",
"r161",
"r234",
"r302"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
"label": "Scenario [Axis]"
}
}
},
"localname": "StatementScenarioAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SubsequentEventsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsAndOtherReceivablesNetCurrent": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 5.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
"label": "Accounts and Other Receivables, Net, Current",
"terseLabel": "Other accounts receivable"
}
}
},
"localname": "AccountsAndOtherReceivablesNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
"auth_ref": [],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 8.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
"label": "Accounts Payable and Other Accrued Liabilities, Current",
"terseLabel": "Other accounts payable"
}
}
},
"localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r41",
"r300"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Trade payables"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsPayableInterestBearingInterestRate": {
"auth_ref": [
"r285",
"r286",
"r287",
"r288"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables.",
"label": "Accounts Payable, Interest-bearing, Interest Rate",
"terseLabel": "Bear interest"
}
}
},
"localname": "AccountsPayableInterestBearingInterestRate",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_AccountsReceivableNetCurrent": {
"auth_ref": [
"r13",
"r34",
"r150",
"r151"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts Receivable, after Allowance for Credit Loss, Current",
"terseLabel": "Trade receivables, net"
}
}
},
"localname": "AccountsReceivableNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableNetNoncurrent": {
"auth_ref": [
"r34",
"r150",
"r315",
"r324"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_AssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.",
"label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent",
"terseLabel": "Other accounts receivable"
}
}
},
"localname": "AccountsReceivableNetNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r51",
"r52",
"r59",
"r60",
"r61",
"r103",
"r104",
"r105",
"r262",
"r339",
"r340",
"r352"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "AOCI Attributable to Parent [Member]",
"terseLabel": "Translation reserve"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r35",
"r245",
"r300"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
"label": "Additional Paid in Capital",
"terseLabel": "Additional paid in capital"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r103",
"r104",
"r105",
"r242",
"r243",
"r244",
"r269"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]",
"terseLabel": "Additional paid in capital"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "stringItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r98",
"r130",
"r135",
"r141",
"r154",
"r162",
"r163",
"r164",
"r165",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r260",
"r263",
"r274",
"r298",
"r300",
"r310",
"r325"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "Assets"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r14",
"r15",
"r49",
"r98",
"r154",
"r162",
"r163",
"r164",
"r165",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r260",
"r263",
"r274",
"r298",
"r300"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsNoncurrent": {
"auth_ref": [
"r20",
"r21",
"r22",
"r23",
"r24",
"r25",
"r26",
"r27",
"r98",
"r154",
"r162",
"r163",
"r164",
"r165",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r260",
"r263",
"r274",
"r298"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
"label": "Assets, Noncurrent",
"totalLabel": "Total non-current assets"
}
}
},
"localname": "AssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting, Policy [Policy Text Block]",
"terseLabel": "Basis of preparation"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/AccountingPoliciesByPolicy"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CapitalUnits": {
"auth_ref": [
"r346"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
"label": "Capital Units, Value",
"terseLabel": "Share capital value"
}
}
},
"localname": "CapitalUnits",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CapitalUnitsMember": {
"auth_ref": [
"r347"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares.",
"label": "Capital Units [Member]",
"terseLabel": "Share capital"
}
}
},
"localname": "CapitalUnitsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "domainItemType"
},
"us-gaap_Cash": {
"auth_ref": [
"r40",
"r300",
"r344",
"r345"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash",
"terseLabel": "Paid bonus amount"
}
}
},
"localname": "Cash",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/RelatedPartiesandShareholdersDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r11",
"r40",
"r91"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
"auth_ref": [
"r86",
"r277"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
"totalLabel": "Increase (decrease) in cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashEquivalentsAtCarryingValue": {
"auth_ref": [
"r40"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash Equivalents, at Carrying Value",
"periodEndLabel": "Cash and cash equivalents at the end of the period",
"periodStartLabel": "Cash and cash equivalents at beginning of the period"
}
}
},
"localname": "CashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r103",
"r104",
"r269"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common Stock [Member]"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable",
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r33"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Ordinary share par value (in Dollars per share)",
"verboseLabel": "Par value"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails",
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r33"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Authorized, ordinary shares",
"verboseLabel": "Ordinary shares authorized (in Shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable",
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r33"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"terseLabel": "Ordinary shares",
"verboseLabel": "Shares issued"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/RelatedPartiesandShareholdersDetails",
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r33",
"r210"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock, Shares, Outstanding",
"terseLabel": "Issued and outstanding, warrants"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r33",
"r300"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock, Value, Issued",
"terseLabel": "Ordinary shares"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommonStockValueOutstanding": {
"auth_ref": [
"r33"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
"label": "Common Stock, Value, Outstanding",
"terseLabel": "Outstanding debt"
}
}
},
"localname": "CommonStockValueOutstanding",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r55",
"r57",
"r58",
"r68",
"r320",
"r334"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
"totalLabel": "Total comprehensive loss for the period"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
"auth_ref": [
"r55",
"r57",
"r67",
"r259",
"r266",
"r319",
"r333"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
"terseLabel": "Total comprehensive loss for the period"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertibleDebt": {
"auth_ref": [
"r30",
"r312",
"r326"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
"label": "Convertible Debt",
"negatedPeriodEndLabel": "Convertible debenture as of June 30, 2021",
"negatedPeriodStartLabel": "Convertible debenture as of December 31, 2020",
"terseLabel": "Convertible debenture"
}
}
},
"localname": "ConvertibleDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3intheconvertibledebenturefinancialstatementsTable",
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertibleDebtCurrent": {
"auth_ref": [
"r28"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
"label": "Convertible Debt, Current",
"terseLabel": "Convertible debenture"
}
}
},
"localname": "ConvertibleDebtCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertibleDebtMember": {
"auth_ref": [
"r173",
"r175",
"r176",
"r178",
"r182",
"r183",
"r184",
"r187",
"r188",
"r189",
"r190",
"r191",
"r193",
"r194",
"r195",
"r196"
],
"lang": {
"en-us": {
"role": {
"documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
"label": "Convertible Debt [Member]",
"terseLabel": "Convertible debenture [Member]"
}
}
},
"localname": "ConvertibleDebtMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3intheconvertibledebenturefinancialstatementsTable"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConvertibleDebtNoncurrent": {
"auth_ref": [
"r45"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
"label": "Convertible Debt, Noncurrent",
"negatedLabel": "Convertible debenture"
}
}
},
"localname": "ConvertibleDebtNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostOfGoodsAndServicesSold": {
"auth_ref": [
"r71",
"r308"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 2.0,
"parentTag": "us-gaap_CostOfRevenue",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
"label": "Cost of Goods and Services Sold",
"terseLabel": "Cost of sales of products"
}
}
},
"localname": "CostOfGoodsAndServicesSold",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostOfRevenue": {
"auth_ref": [
"r72",
"r98",
"r154",
"r162",
"r163",
"r164",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r274"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 2.0,
"parentTag": "us-gaap_GrossProfit",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
"label": "Cost of Revenue",
"totalLabel": "Total cost of revenue"
}
}
},
"localname": "CostOfRevenue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostOfRevenueAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Cost of Revenue [Abstract]",
"terseLabel": "Cost of revenue:"
}
}
},
"localname": "CostOfRevenueAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtConversionConvertedInstrumentAmount1": {
"auth_ref": [
"r92",
"r93"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
"label": "Debt Conversion, Converted Instrument, Amount",
"terseLabel": "Conversion of loans into shares"
}
}
},
"localname": "DebtConversionConvertedInstrumentAmount1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r28",
"r29",
"r30",
"r97",
"r101",
"r175",
"r176",
"r177",
"r178",
"r179",
"r180",
"r181",
"r182",
"r183",
"r184",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r191",
"r193",
"r194",
"r195",
"r196",
"r289",
"r311",
"r312",
"r323"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
"auth_ref": [
"r192"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
"label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
"terseLabel": "Convertible loan amount"
}
}
},
"localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
"label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
"terseLabel": "Conversion price, percentage"
}
}
},
"localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentInterestRateStatedPercentage": {
"auth_ref": [
"r44",
"r176"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
"label": "Debt Instrument, Interest Rate, Stated Percentage",
"terseLabel": "Interest rate"
}
}
},
"localname": "DebtInstrumentInterestRateStatedPercentage",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r45",
"r97",
"r101",
"r175",
"r176",
"r177",
"r178",
"r179",
"r180",
"r181",
"r182",
"r183",
"r184",
"r185",
"r186",
"r187",
"r188",
"r189",
"r190",
"r191",
"r193",
"r194",
"r195",
"r196",
"r289"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument, Name [Domain]"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DeferredIncomeTaxExpenseBenefit": {
"auth_ref": [
"r89",
"r99",
"r249",
"r253",
"r254",
"r255"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 4.0,
"parentTag": "gmvd_AdjustmentstoCashProvidedbyUsedinOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
"label": "Deferred Income Tax Expense (Benefit)",
"terseLabel": "Changes in deferred tax"
}
}
},
"localname": "DeferredIncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationDepletionAndAmortization": {
"auth_ref": [
"r89",
"r128"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 1.0,
"parentTag": "gmvd_AdjustmentstoCashProvidedbyUsedinOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
"label": "Depreciation, Depletion and Amortization",
"terseLabel": "Depreciation and amortization"
}
}
},
"localname": "DepreciationDepletionAndAmortization",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
"auth_ref": [
"r268"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
"label": "Derivative Assets (Liabilities), at Fair Value, Net",
"negatedLabel": "Derivative liability - warrants"
}
}
},
"localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeForwardExchangeRate1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual rate at which a foreign currency can be purchased or sold.",
"label": "Derivative, Forward Exchange Rate",
"terseLabel": "Exchange rate"
}
}
},
"localname": "DerivativeForwardExchangeRate1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/FairValueMeasurementDetails"
],
"xbrltype": "pureItemType"
},
"us-gaap_DerivativeLiabilitiesCurrent": {
"auth_ref": [
"r50"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 5.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
"label": "Derivative Liability, Current",
"terseLabel": "Derivative liabilities \u2013 warrants"
}
}
},
"localname": "DerivativeLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeLiabilitiesNoncurrent": {
"auth_ref": [
"r50"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
"label": "Derivative Liability, Noncurrent",
"periodEndLabel": "Derivative liability - warrants as of June 30, 2021",
"periodStartLabel": "Derivative liability - warrants as of December 31, 2020"
}
}
},
"localname": "DerivativeLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EarningsPerShareBasicAndDiluted": {
"auth_ref": [
"r120"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Basic and Diluted",
"terseLabel": "Basic and diluted loss per share attributable to the Company\u2019s shareholders in USD (in Dollars per share)"
}
}
},
"localname": "EarningsPerShareBasicAndDiluted",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
"auth_ref": [
"r277"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
"label": "Effect of Exchange Rate on Cash and Cash Equivalents",
"terseLabel": "Effects of exchange rate changes on cash and cash equivalents"
}
}
},
"localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"auth_ref": [
"r241"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
"terseLabel": "Vested period"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SubsequentEventsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r59",
"r60",
"r61",
"r103",
"r104",
"r105",
"r107",
"r112",
"r114",
"r122",
"r155",
"r210",
"r211",
"r242",
"r243",
"r244",
"r250",
"r251",
"r269",
"r278",
"r279",
"r280",
"r281",
"r282",
"r284",
"r339",
"r340",
"r341",
"r352"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails",
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3",
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r184",
"r193",
"r194",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r231",
"r233",
"r272",
"r304",
"r305",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Hierarchy and NAV [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r273"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"terseLabel": "FAIR VALUE MEASUREMENT"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/FairValueMeasurement"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r184",
"r225",
"r226",
"r231",
"r233",
"r272",
"r304"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value, Inputs, Level 1 [Member]",
"terseLabel": "Level 1 [Member]"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r184",
"r193",
"r194",
"r225",
"r226",
"r231",
"r233",
"r272",
"r305"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value, Inputs, Level 2 [Member]",
"terseLabel": "Level 2 [Member]"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r184",
"r193",
"r194",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r231",
"r233",
"r272",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Inputs, Level 3 [Member]",
"terseLabel": "Level 3 [Member]"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r184",
"r193",
"r194",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r231",
"r233",
"r304",
"r305",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Hierarchy and NAV [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofliabilitiesthataremeasuredatfairvalueinthefinancialstatementsTable"
],
"xbrltype": "domainItemType"
},
"us-gaap_FinanceLeaseLiabilityCurrent": {
"auth_ref": [
"r290"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 7.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
"label": "Finance Lease, Liability, Current",
"terseLabel": "Financial liability"
}
}
},
"localname": "FinanceLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossRealized": {
"auth_ref": [
"r275",
"r276"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain (Loss), Realized",
"terseLabel": "Exchange gains arising on translation of foreign operations"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossRealized",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GainLossOnDispositionOfAssets": {
"auth_ref": [
"r89",
"r158",
"r160"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 6.0,
"parentTag": "gmvd_AdjustmentstoCashProvidedbyUsedinOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
"label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
"negatedLabel": "Capital loss from sale of fixed assets"
}
}
},
"localname": "GainLossOnDispositionOfAssets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GainsLossesOnRestructuringOfDebt": {
"auth_ref": [
"r197"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 7.0,
"parentTag": "gmvd_AdjustmentstoCashProvidedbyUsedinOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
"label": "Gains (Losses) on Restructuring of Debt",
"negatedLabel": "Accrued interest of long-term loans"
}
}
},
"localname": "GainsLossesOnRestructuringOfDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r74"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General and Administrative Expense",
"terseLabel": "Unallocated general and administrative expenses"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GrossProfit": {
"auth_ref": [
"r70",
"r98",
"r130",
"r134",
"r137",
"r140",
"r143",
"r154",
"r162",
"r163",
"r164",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r274"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
"label": "Gross Profit",
"totalLabel": "Gross profit (loss)"
}
}
},
"localname": "GrossProfit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IPOMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "First sale of stock by a private company to the public.",
"label": "IPO [Member]",
"terseLabel": "IPO [Member]",
"verboseLabel": "Initial Public Offering [Member]"
}
}
},
"localname": "IPOMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails",
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeLossAttributableToParent": {
"auth_ref": [
"r61",
"r73"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
"label": "Income (Loss) Attributable to Parent, before Tax",
"terseLabel": "Loss before taxes on income"
}
}
},
"localname": "IncomeLossAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
"auth_ref": [
"r257",
"r259"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 2.0,
"parentTag": "gmvd_TotalComprehensivelossForThePeriod",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
"label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
"negatedLabel": "Non-controlling interests"
}
}
},
"localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"auth_ref": [
"r64",
"r130",
"r134",
"r137",
"r140",
"r143",
"r309",
"r316",
"r321",
"r335"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
"label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"terseLabel": "Loss before tax"
}
}
},
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
"auth_ref": [
"r2",
"r3",
"r4",
"r5",
"r6",
"r7",
"r8",
"r259"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
"label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
"totalLabel": "Total loss"
}
}
},
"localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxExpenseBenefit": {
"auth_ref": [
"r100",
"r113",
"r114",
"r129",
"r248",
"r252",
"r256",
"r336"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Income Tax Expense (Benefit)",
"negatedLabel": "Income tax benefit"
}
}
},
"localname": "IncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
"label": "Increase (Decrease) in Accounts Payable, Trade",
"terseLabel": "Increase (decrease) in trade payables"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableTrade",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 3.0,
"parentTag": "gmvd_AdjustmentstoCashProvidedbyUsedinOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
"label": "Increase (Decrease) in Derivative Liabilities",
"negatedLabel": "Gain due to change in fair value of convertible debenture",
"terseLabel": "Change in fair value of derivative liabilities \u2013 warrants",
"verboseLabel": "Issuance of financial instruments"
}
}
},
"localname": "IncreaseDecreaseInDerivativeLiabilities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0",
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3intheconvertibledebenturefinancialstatementsTable",
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInInterestPayableNet": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
"label": "Increase (Decrease) in Interest Payable, Net",
"terseLabel": "Accrued interest on loan from controlling shareholder"
}
}
},
"localname": "IncreaseDecreaseInInterestPayableNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
"label": "Increase (Decrease) in Other Accounts Payable",
"terseLabel": "Increase (decrease) in other accounts payable"
}
}
},
"localname": "IncreaseDecreaseInOtherAccountsPayable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryNet": {
"auth_ref": [
"r12",
"r48",
"r300"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Inventory, Net",
"terseLabel": "Inventories"
}
}
},
"localname": "InventoryNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r39",
"r98",
"r154",
"r274",
"r300",
"r314",
"r329"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total Liabilities and Shareholders\u2019 Equity (Deficit)"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r43",
"r98",
"r154",
"r162",
"r163",
"r164",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r261",
"r263",
"r264",
"r274",
"r298",
"r299",
"r300"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesFairValueAdjustment": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
"label": "Liabilities, Fair Value Adjustment",
"terseLabel": "Change in fair value"
}
}
},
"localname": "LiabilitiesFairValueAdjustment",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesNoncurrent": {
"auth_ref": [
"r16",
"r17",
"r18",
"r30",
"r31",
"r98",
"r154",
"r162",
"r163",
"r164",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r261",
"r263",
"r264",
"r274",
"r298",
"r299"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
"label": "Liabilities, Noncurrent",
"totalLabel": "Total non-current liabilities"
}
}
},
"localname": "LiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtAndCapitalLeaseObligations": {
"auth_ref": [
"r30"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
"label": "Long-term Debt and Lease Obligation",
"terseLabel": "Long term lease liability"
}
}
},
"localname": "LongTermDebtAndCapitalLeaseObligations",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MinorityInterest": {
"auth_ref": [
"r47",
"r98",
"r154",
"r162",
"r166",
"r167",
"r168",
"r171",
"r172",
"r274",
"r313",
"r328"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
"label": "Stockholders' Equity Attributable to Noncontrolling Interest",
"terseLabel": "Non-controlling interest"
}
}
},
"localname": "MinorityInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r86"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
"terseLabel": "Cash flow from financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r86"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash used in / provided by investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
"terseLabel": "Cash flow from investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r86",
"r87",
"r90"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Cash flow from operating activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
"auth_ref": [
"r86",
"r87",
"r90"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
"totalLabel": "Total assets and liabilities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r9",
"r53",
"r56",
"r61",
"r65",
"r90",
"r98",
"r106",
"r108",
"r109",
"r110",
"r111",
"r113",
"r114",
"r118",
"r130",
"r134",
"r137",
"r140",
"r143",
"r154",
"r162",
"r163",
"r164",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r270",
"r274",
"r317",
"r331"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss) Attributable to Parent",
"terseLabel": "Loss for the period",
"totalLabel": "Loss for the period",
"verboseLabel": "Net loss for the period"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0",
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement",
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
"auth_ref": [
"r108",
"r109",
"r110",
"r111",
"r116",
"r117",
"r119",
"r121",
"r130",
"r134",
"r137",
"r140",
"r143"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 1.0,
"parentTag": "gmvd_TotalComprehensivelossForThePeriod",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
"label": "Net Income (Loss) Available to Common Stockholders, Basic",
"terseLabel": "The Company\u2019s shareholders"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "Impact of accounting standards to be applied in future periods"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/AccountingPoliciesByPolicy"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NoncontrollingInterestMember": {
"auth_ref": [
"r103",
"r104",
"r105",
"r211",
"r257"
],
"lang": {
"en-us": {
"role": {
"documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
"label": "Noncontrolling Interest [Member]",
"terseLabel": "Non-controlling Interest"
}
}
},
"localname": "NoncontrollingInterestMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "domainItemType"
},
"us-gaap_NonoperatingIncomeExpense": {
"auth_ref": [
"r75"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
"label": "Nonoperating Income (Expense)",
"totalLabel": "Financial expenses, net"
}
}
},
"localname": "NonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingExpensesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Operating Expenses [Abstract]",
"terseLabel": "Operating expenses:"
}
}
},
"localname": "OperatingExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r130",
"r134",
"r137",
"r140",
"r143"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Operating loss"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
"auth_ref": [
"r10",
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
"label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
"terseLabel": "DESCRIPTION OF BUSINESS"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/DescriptionofBusiness"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherAdditionalCapitalMember": {
"auth_ref": [
"r77",
"r174"
],
"lang": {
"en-us": {
"role": {
"documentation": "This element represents a category to capture additional Paid-in Capital other than attributable to capital contributed by shareholders in excess of the par or stated value of the common or preferred stock issued by an entity. Certain entities report two components of additional Paid-in Capital consisting of (i) capital in excess of par or stated value and (ii) other additional capital. This member is only to be used if the entity distinguishes between additional Paid-in Capital and other additional capital in its financial statements. If using this element, the preparer would be expected to elevate the Other Additional Capital [Member] to the same level as the Additional Paid-in Capital [Member].",
"label": "Other Additional Capital [Member]",
"terseLabel": "Other reserve"
}
}
},
"localname": "OtherAdditionalCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
"auth_ref": [
"r59",
"r60",
"r66",
"r153",
"r278",
"r283",
"r284",
"r318",
"r332"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
"label": "Other Comprehensive Income (Loss), before Tax",
"terseLabel": "Other comprehensive income"
}
}
},
"localname": "OtherComprehensiveIncomeLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r54",
"r57",
"r59",
"r60",
"r62",
"r66",
"r210",
"r278",
"r283",
"r284",
"r318",
"r332"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
"label": "Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Other comprehensive income"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNoncashExpense": {
"auth_ref": [
"r90"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
"label": "Other Noncash Expense",
"terseLabel": "Non-cash issuance expenses in warrants"
}
}
},
"localname": "OtherNoncashExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r76"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 1.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense)",
"terseLabel": "Finance expenses"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
"auth_ref": [
"r79"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
"label": "Payments to Acquire Businesses, Net of Cash Acquired",
"negatedLabel": "Deposit in restricted deposit"
}
}
},
"localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"auth_ref": [
"r80"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
"label": "Payments to Acquire Property, Plant, and Equipment",
"negatedLabel": "Purchase of property, plant and equipment"
}
}
},
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromConvertibleDebt": {
"auth_ref": [
"r82"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
"label": "Proceeds from Convertible Debt",
"negatedLabel": "issuance of convertible debenture",
"terseLabel": "Receipt (repayment (convertible debenture"
}
}
},
"localname": "ProceedsFromConvertibleDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0",
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3intheconvertibledebenturefinancialstatementsTable"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromDerivativeInstrumentFinancingActivities": {
"auth_ref": [
"r83",
"r85"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow provided by derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
"label": "Proceeds from Derivative Instrument, Financing Activities",
"terseLabel": "Receipt of derivative liabilities \u2013 warrants"
}
}
},
"localname": "ProceedsFromDerivativeInstrumentFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"auth_ref": [
"r81"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the additional capital contribution to the entity.",
"label": "Proceeds from Issuance of Common Stock",
"terseLabel": "Issuance of ordinary shares, net"
}
}
},
"localname": "ProceedsFromIssuanceOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
"auth_ref": [
"r82"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
"label": "Proceeds from Issuance of Other Long-term Debt",
"terseLabel": "Receipts of long-term loans"
}
}
},
"localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromRelatedPartyDebt": {
"auth_ref": [
"r82"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
"label": "Proceeds from Related Party Debt",
"terseLabel": "Loan received from controlling shareholder"
}
}
},
"localname": "ProceedsFromRelatedPartyDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleOfPropertyHeldForSale": {
"auth_ref": [
"r78"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.",
"label": "Proceeds from Sale of Property Held-for-sale",
"terseLabel": "Proceeds from sale of fixed assets"
}
}
},
"localname": "ProceedsFromSaleOfPropertyHeldForSale",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProductMember": {
"auth_ref": [
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "Article or substance produced by nature, labor or machinery.",
"label": "Product [Member]",
"terseLabel": "Product [Member]"
}
}
},
"localname": "ProductMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "domainItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r23",
"r24",
"r159",
"r300",
"r322",
"r330"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_AssetsNoncurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"terseLabel": "Property, plant and equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProvisionForDoubtfulAccounts": {
"auth_ref": [
"r69",
"r156"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 4.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
"label": "Accounts Receivable, Credit Loss Expense (Reversal)",
"terseLabel": "Expected credit loss"
}
}
},
"localname": "ProvisionForDoubtfulAccounts",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RelatedPartyTransactionAxis": {
"auth_ref": [
"r232",
"r293",
"r294",
"r295"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of related party transaction.",
"label": "Related Party Transaction [Axis]"
}
}
},
"localname": "RelatedPartyTransactionAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionDomain": {
"auth_ref": [
"r232"
],
"lang": {
"en-us": {
"role": {
"documentation": "Transaction between related party.",
"label": "Related Party Transaction [Domain]"
}
}
},
"localname": "RelatedPartyTransactionDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RelatedPartyTransactionsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Related Party Transactions [Abstract]"
}
}
},
"localname": "RelatedPartyTransactionsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
"auth_ref": [
"r291",
"r292",
"r294",
"r296",
"r297"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
"label": "Related Party Transactions Disclosure [Text Block]",
"terseLabel": "RELATED PARTIES AND SHAREHOLDERS"
}
}
},
"localname": "RelatedPartyTransactionsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/RelatedPartiesandShareholders"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RepaymentsOfDebt": {
"auth_ref": [
"r84"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
"label": "Repayments of Debt",
"negatedLabel": "Principal paid on lease liabilities"
}
}
},
"localname": "RepaymentsOfDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfLinesOfCredit": {
"auth_ref": [
"r84",
"r97"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
"label": "Repayments of Lines of Credit",
"negatedLabel": "Short-term bank credit"
}
}
},
"localname": "RepaymentsOfLinesOfCredit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfLongTermDebt": {
"auth_ref": [
"r84"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
"label": "Repayments of Long-term Debt",
"negatedLabel": "Repayment of long -term loans"
}
}
},
"localname": "RepaymentsOfLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r247",
"r307",
"r348"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and Development Expense",
"terseLabel": "Research and development expenses"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r11",
"r19",
"r91",
"r94"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Restricted Cash and Cash Equivalents, Current",
"terseLabel": "Restricted deposit"
}
}
},
"localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r36",
"r211",
"r245",
"r300",
"r327",
"r342",
"r343"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 5.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings (Accumulated Deficit)",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r103",
"r104",
"r105",
"r107",
"r112",
"r114",
"r155",
"r242",
"r243",
"r244",
"r250",
"r251",
"r269",
"r339",
"r341"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Revenue from Contract with Customer [Abstract]"
}
}
},
"localname": "RevenueFromContractWithCustomerAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RevenueFromContractWithCustomerTextBlock": {
"auth_ref": [
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r220",
"r222",
"r224"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
"label": "Revenue from Contract with Customer [Text Block]",
"terseLabel": "REVENUE"
}
}
},
"localname": "RevenueFromContractWithCustomerTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/Revenue"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Revenues": {
"auth_ref": [
"r63",
"r98",
"r126",
"r127",
"r133",
"r138",
"r139",
"r145",
"r146",
"r148",
"r154",
"r162",
"r163",
"r164",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r274",
"r321"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 1.0,
"parentTag": "us-gaap_GrossProfit",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
"label": "Revenues",
"totalLabel": "Total revenue"
}
}
},
"localname": "Revenues",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SaleOfStockNameOfTransactionDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
"label": "Sale of Stock [Domain]"
}
}
},
"localname": "SaleOfStockNameOfTransactionDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails",
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
"label": "Sale of Stock, Number of Shares Issued in Transaction",
"terseLabel": "Initial public offering (in Shares)",
"verboseLabel": "Number of shares"
}
}
},
"localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails",
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SaleOfStockPricePerShare": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
"label": "Sale of Stock, Price Per Share",
"terseLabel": "Exercisable price per share"
}
}
},
"localname": "SaleOfStockPricePerShare",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of derivative liabilities at fair value.",
"label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
"terseLabel": "Schedule of liabilities that are measured at level 3 in the derivative liability warrants financial statements"
}
}
},
"localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/FairValueMeasurementTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
"auth_ref": [
"r271",
"r272"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
"terseLabel": "Schedule of liabilities that are measured at fair value in the financial statements"
}
}
},
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/FairValueMeasurementTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
"auth_ref": [
"r130",
"r131",
"r136",
"r157"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
"label": "Schedule of Segment Reporting Information, by Segment [Table]"
}
}
},
"localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
"auth_ref": [
"r130",
"r131",
"r136",
"r157"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
"label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
"terseLabel": "Schedule of products and patient services"
}
}
},
"localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SegmentReportingTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShortTermDebtTable": {
"auth_ref": [
"r42"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
"label": "Schedule of Short-term Debt [Table]"
}
}
},
"localname": "ScheduleOfShortTermDebtTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3intheconvertibledebenturefinancialstatementsTable"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShortTermDebtTextBlock": {
"auth_ref": [
"r42"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
"label": "Schedule of Short-term Debt [Table Text Block]",
"terseLabel": "Schedule of liabilities that are measured at level 3 in the convertible debenture financial statements"
}
}
},
"localname": "ScheduleOfShortTermDebtTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/FairValueMeasurementTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
"auth_ref": [
"r210"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
"label": "Schedule of Stockholders Equity [Table Text Block]",
"terseLabel": "Schedule of confer upon their holders the right to receive notice to participate and vote in general meetings"
}
}
},
"localname": "ScheduleOfStockholdersEquityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SegmentReportingAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Segment Reporting [Abstract]"
}
}
},
"localname": "SegmentReportingAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_SegmentReportingDisclosureTextBlock": {
"auth_ref": [
"r123",
"r124",
"r125",
"r130",
"r132",
"r137",
"r141",
"r142",
"r143",
"r144",
"r145",
"r147",
"r148",
"r149"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
"label": "Segment Reporting Disclosure [Text Block]",
"terseLabel": "SEGMENT REPORTING"
}
}
},
"localname": "SegmentReportingDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SegmentReporting"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SegmentReportingInformationLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Segment Reporting Information [Line Items]"
}
}
},
"localname": "SegmentReportingInformationLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofproductsandpatientservicesTable"
],
"xbrltype": "stringItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpense": {
"auth_ref": [
"r74"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement": {
"order": 3.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
"label": "Selling, General and Administrative Expense",
"terseLabel": "Selling, general and administrative expenses"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedIncomeStatement"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0": {
"order": 2.0,
"parentTag": "gmvd_AdjustmentstoCashProvidedbyUsedinOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-based Payment Arrangement, Noncash Expense",
"terseLabel": "Share based compensation"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow0"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
"auth_ref": [
"r238"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
"terseLabel": "Expected volatility"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/FairValueMeasurementDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
"auth_ref": [
"r239"
],
"lang": {
"en-us": {
"role": {
"documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
"terseLabel": "Risk-free interest rate"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/FairValueMeasurementDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
"auth_ref": [
"r236"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
"label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
"terseLabel": "Issued options shares"
}
}
},
"localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SubsequentEventsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
"auth_ref": [
"r240"
],
"lang": {
"en-us": {
"role": {
"documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
"label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
"terseLabel": "Exercise price per share"
}
}
},
"localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SubsequentEventsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharesHeldInEmployeeStockOptionPlanCommittedToBeReleased": {
"auth_ref": [
"r246"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of committed-to-be-released shares held by the Employee Stock Option Plan at balance sheet date. Committed-to-be-released shares are shares that will be released in the future and will be allocated to employees for services rendered in an accounting period. These shares are legally released from suspense and from serving as collateral for ESOP debt as a result of payment of debt service.",
"label": "Shares Held in Employee Stock Option Plan, Committed-to-be-Released",
"terseLabel": "Additional ordinary shares purchase"
}
}
},
"localname": "SharesHeldInEmployeeStockOptionPlanCommittedToBeReleased",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SharesIssuedPricePerShare": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Per share or per unit amount of equity securities issued.",
"label": "Shares Issued, Price Per Share",
"terseLabel": "Price per share"
}
}
},
"localname": "SharesIssuedPricePerShare",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShortTermDebtLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Short-term Debt [Line Items]"
}
}
},
"localname": "ShortTermDebtLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3intheconvertibledebenturefinancialstatementsTable"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShortTermDebtTypeAxis": {
"auth_ref": [
"r42"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of short-term debt arrangement.",
"label": "Short-term Debt, Type [Axis]"
}
}
},
"localname": "ShortTermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3intheconvertibledebenturefinancialstatementsTable"
],
"xbrltype": "stringItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r95",
"r102"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]",
"terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r46",
"r59",
"r60",
"r61",
"r103",
"r104",
"r105",
"r107",
"r112",
"r114",
"r122",
"r155",
"r210",
"r211",
"r242",
"r243",
"r244",
"r250",
"r251",
"r269",
"r278",
"r279",
"r280",
"r281",
"r282",
"r284",
"r339",
"r340",
"r341",
"r352"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable",
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable",
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails",
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3",
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r103",
"r104",
"r105",
"r122",
"r308"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
"label": "Stock Issued During Period, Shares, Purchase of Assets",
"terseLabel": "Ordinary shares purchase (in Shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
"auth_ref": [
"r46",
"r210",
"r211"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
"label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
"terseLabel": "Conversion of loans from controlling shareholder into shares"
}
}
},
"localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"auth_ref": [
"r32",
"r33",
"r210",
"r211"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "Stock Issued During Period, Value, New Issues",
"terseLabel": "Issuance of ordinary shares, net"
}
}
},
"localname": "StockIssuedDuringPeriodValueNewIssues",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueOther": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of shares of stock issued attributable to transactions classified as other.",
"label": "Stock Issued During Period, Value, Other",
"terseLabel": "Conversion of financial liability to shares"
}
}
},
"localname": "StockIssuedDuringPeriodValueOther",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
"auth_ref": [
"r32",
"r33",
"r211",
"r235",
"r237"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
"label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
"terseLabel": "Issuance of shares within share based compensation"
}
}
},
"localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r33",
"r37",
"r38",
"r98",
"r152",
"r154",
"r274",
"r300"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders' Equity Attributable to Parent",
"totalLabel": "G Medical Innovations Holdings Ltd. shareholders\u2019 equity (deficit)"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
"auth_ref": [
"r0",
"r1",
"r60",
"r98",
"r103",
"r104",
"r105",
"r107",
"r112",
"r154",
"r155",
"r211",
"r242",
"r243",
"r244",
"r250",
"r251",
"r257",
"r258",
"r265",
"r269",
"r274",
"r278",
"r279",
"r284",
"r340",
"r341",
"r352"
],
"calculation": {
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
"label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
"periodEndLabel": "Balance",
"periodStartLabel": "Balance",
"totalLabel": "Total shareholders\u2019 equity (deficit)"
}
}
},
"localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ConsolidatedCashFlow",
"http://www.gmedinnovations.com/role/ShareholdersEquityType2or3"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityNoteAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity Note [Abstract]"
}
}
},
"localname": "StockholdersEquityNoteAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r96",
"r198",
"r199",
"r200",
"r201",
"r202",
"r203",
"r204",
"r205",
"r206",
"r207",
"r208",
"r209",
"r211",
"r212"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders' Equity Note Disclosure [Text Block]",
"terseLabel": "SHAREHOLDERS' EQUITY (DEFICIT)"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficit"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsequentEventsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Subsequent Events [Abstract]"
}
}
},
"localname": "SubsequentEventsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventsTextBlock": {
"auth_ref": [
"r301",
"r303"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
"label": "Subsequent Events [Text Block]",
"terseLabel": "SUBSEQUENT EVENTS"
}
}
},
"localname": "SubsequentEventsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/SubsequentEvents"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsidiarySaleOfStockAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of sale of the entity's stock.",
"label": "Sale of Stock [Axis]"
}
}
},
"localname": "SubsidiarySaleOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails",
"http://www.gmedinnovations.com/role/SignificantEventsandTransactionsinthePeriodDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_WarrantMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
"label": "Warrant [Member]",
"terseLabel": "Warrant [Member]",
"verboseLabel": "Derivative liability warrants [Member]"
}
}
},
"localname": "WarrantMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.gmedinnovations.com/role/ScheduleofconferupontheirholderstherighttoreceivenoticetoparticipateandvoteingeneralmeetingsTable",
"http://www.gmedinnovations.com/role/Scheduleofliabilitiesthataremeasuredatlevel3inthederivativeliabilitywarrantsfinancialstatementsTable",
"http://www.gmedinnovations.com/role/ShareholdersEquityDeficitDetails"
],
"xbrltype": "domainItemType"
}
},
"unitCount": 4
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "105",
"URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
},
"r10": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "205",
"URI": "http://asc.fasb.org/topic&trid=2122149"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r102": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "http://asc.fasb.org/topic&trid=2122369"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.M.Q2)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "26",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "34",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
},
"r149": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "280",
"URI": "http://asc.fasb.org/topic&trid=2134510"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "323",
"URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 201.5-02(24))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 201.5-02(25))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4815-112606"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 201.5-02(26))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "69E",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "69F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "60",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(10))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(11))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r212": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "http://asc.fasb.org/topic&trid=2208762"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(12))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
},
"r224": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "606",
"URI": "http://asc.fasb.org/topic&trid=49130388"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(13))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(n)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(f)(3)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(iii)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(14))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(g)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(15))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.7)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.7)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.1)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.2)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(16))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "4I",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "4K",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
},
"r267": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "810",
"URI": "http://asc.fasb.org/topic&trid=2197479"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=29642582&loc=d3e27862-108397"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=29642582&loc=d3e27881-108397"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
},
"r297": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "850",
"URI": "http://asc.fasb.org/topic&trid=2122745"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "855",
"URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
},
"r303": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "855",
"URI": "http://asc.fasb.org/topic&trid=2122774"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "940",
"URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(23))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(22))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(9))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(15))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(24))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(5))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(24))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(19))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(20))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(9))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "4H",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04.16(a))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04.16)",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r349": {
"Name": "Regulation 12B",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Regulation S-X (SX)",
"Number": "210",
"Publisher": "SEC",
"Section": "11",
"Subsection": "03"
},
"r351": {
"Name": "Rule 15c3-1",
"Number": "240",
"Publisher": "SEC",
"Section": "15c3-1"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "3B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.1)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.6(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.9)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(1))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(10))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(21))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(22))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(5))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "5B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.1,2)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2(a),(d))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.20)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.T)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868742-224227"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "5C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3505-108585"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
}
},
"version": "2.1"
}
ZIP
48
0001213900-21-048211-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001213900-21-048211-xbrl.zip
M4$L#!!0 ( #> +U,\-G(;!@T &1I 8 96$Q-#89'V"% $EH"*9 FV9V=.[(M
M0*VQJ27SR*>_1[)-@)"$M*0A6W9V4K"/CGY'Y_@\A"07_YP.+30F+J..?135
MXFH4$=MP3&KWCZ+E3J5>C_Y9BA3_$XNA4V(3%W-B(GV&*LYPU#$HZKK89CW'
M':)W?/@>Q=" \U%>42:32=P &F90ES#'RS6QW@T;]'#3)?4P0TYF#%56^@!
M[O#9B+"U;>2=-8T$"G-%R0&HC.+?7"2ECRG+9AS;QER$J?4(\74#!+ZC7!V<
M25*2:KE<3I%WYZ1L'1VPU)3K\T;'&) ACMU#PNCS6SV,1SQ,<]9#:QTA46*:&BXG^(1(I#PC$R')L3&\R6DRE7_(X$
M]QCYYM'Q4;3BWX]U09U1I,"3K?AXM!>5K00"1?Q;'#V700$-L=NG=AX)4K6 !/88MF@?
M+AF EKC0AS):Z4=XL!-*+/!?;<\BL0O<)\)9+F.:Q+7YW1L8>,K2@!8YEC4G-\,^?KWM?!^
MM/3';UI&+02X[Z%7[L'?PF &,@OHJU*+:^N&.$2Y.M _$T-1+UTVZ]U:%76Z
MY6ZM4U3T-:K_R8@ZM&[RREOD]Y1U("\
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M,)(T:H'1V ,"'%W4X?'73W>>8;IM,G#D?93%;5U/0!)",N)M:2N;ZJ799-
MTR6,"9L KF@P(A',_IM\]E3+0,)&>3:AE^6$'V[:'K8@K$TV&
M_)S)<,;PU\\ZAU#GQ$Y$(_DE!5_BKS)P6YWON!-LR>CEM$0/#ZDURS\U+?/'
M;[EL*E,(K-Z'O\E?T74D]>-=IPKS!^[?:L:TMVK!E"'FZ4/*.93B\J;4)!20
M$6JC$89(C#!#\(^@\6?R(9A[?I!BJ!/K!J6*JKW3W[_3WN?W:GA]-63?N!J^
MF_/NS;O.YU4?F'>=S\N^RKSK(P/W9M4LAJ@ #;]YQ#:$8N[&2_X6X3=X0/U:
M8DUFE%E0[3Q]I[\[P1;@!F#GG3X$0G<)_AK3"=1 @'DD95@$EEF#2X!]
ML-N%T5_?^:)MO9A9Z7,<6\UB'__Q9?/4N])J=FO-;N=ER95(2E
MNE ':**(SIG< 4^R:=#+@,XH3:&Z@'RXPZ'"V)VBXFX!NP_>#9!2?5 _HA_
M DW-08B+&+.,81.$T'Z3:#LQ6+*<4!URE$N%]<* 0G&,;#%CPFP.K4F9X
M_GP0MDU4MK$U V&DY',8 B?E(4V;,,_RI6V-B!O$UEXPE\?HU)_/8XB =.9W
M0DX49%\ &W!?B+(*B@6+8 9UO=" *31P-UVHI4/^\I=3$PD!$VKA%)T3D5Q8
M,.;S90?HS+'$0@R&&MR,HW90A,SEG4L8RM0!FE5VL4Z. Q%2>/PA-1XBF+464L)44^A>.@#^W#H='K79]
M5C^N=U&]6:U=_^PGCF,=JA"#6-8(F_Z:,#4JOXM5(>'W9_>^D'_/'P##L2P\
M8F JX:>H4&Z1NR'_,7&Y<)'A(($510/]<_/Y(%8>/'WUP2L(O\A)3*Y_R2/;
MF;AXM#+7O7D=YI>=86WA/Y2@7-^[^L,O16DZ\:4);6Y^MXC;Q!H:R(^C6IOC
MO"Q4^..NV-+F:+=J=;NIDMU$]2\P%' RX%3ZK@,EBG!PCIM';E]_EU!3!XGD
MX4$BG7[_(RXL\*.YW[_57C;-+!P_$08>F%C*V(T<,7OJ01K
MJ6PRFR'37"ZF_4^N- :KB0_X,%K:H R85T3/+]/0XV5:4<&E^,L^#GO/N?><
M.^ YM^PN$WM3VK)?3*SZ18E_<]_XG1-(:(,))(GDH0F798<:%QYU[U#?/JJ]
M0_VY#C6Y-Z4M.]3DBD.5,]5H9:9:GZ'U">@K3F'?FY9?-X4=#V>FU_K;R-[=
MOBU4K^9NMV@I;\7;:JH6KS<[_UYCVB:JNMPQ*Y&(;;/@Z/P]ERAH
M]HG=(ZZF4SG;?17M JI55]/%4\=VAC-4FW)BRS+6W_B]]SU[5'O?LXGOJ90;
MNZ^B74"U@>^I8,L(EBNC1G#XQ]X3[5'M/=$FGJA:.]E]%>T"J@T\497TJ$WW
MCFC'-/=64/W:CJA1/MY]%>T"J@T<40/KQ-K[H!U2VEM!]6O[H(MV;?=5M NH
M-O!!XF<]\#G[NFS7=/=64/W*KBBU^^K9!505802QXO]Y#*7(;2K UY47W
MVSRT#^:176+)7V9#6&*_(6SS;5L[O4VZ4S]MEKN7[=HOL5$Z/( |